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General introduction
Acute lymphoblastic leukemia (ALL) is the most common form of cancer in 
children, with 110 – 120 newly diagnosed children in the Netherlands each 
year. ALL is a haematological malignancy of lymphoid precursor cells and can be 
divided into two sub-groups: B-cell precursor ALL and T-cell precursor ALL. These 
two subgroups can be differentiated using light microscopy (morphology and 
cytochemical staining) and immunophenotypic classifi cation. More recently, other 
subgroups have been identifi ed based on genetic abnormalities in the leukemic 
cells such as chromosomal translocations (BCR-ABL, TEL-AML1, E2A-PBX1, MLL-
gene rearranged) and chromosome copy number (hyperdiploidy). Both a favorable 
(TEL-AML1, hyperdiploidy) and unfavorable (BCR-ABL, MLL-gene rearranged ALL) 
prognosis have been linked to these genetic subtypes. The prognosis for children 
with ALL has increased signifi cantly over the past 35 years, with a 5-year event-
free survival of 75-80% in most current treatment protocols. (Figure 1) However, 
still 20-25% of the children relapses, with a signifi cantly worse prognosis for 
survival. In most international treatment protocols, patients are divided into three 
risk-groups, i.e. standard risk, intermediate risk and poor risk. Traditional risk 
factors for this stratifi cation are: white blood cell count at diagnosis (<50 x 109/l 
or ≥50 x 109/l), age (< 1 year, 1-9 year or ≥10 year), central nervous system 
Figure 1. Event free survival in childhood ALL
Kaplan-Meier analysis of event-free survival (EFS) in 2255 children with ALL who were 
enrolled in 13 consecutive treatment protocols conducted at the St Jude Children’s Research 
Hospital from 1962 – 1997. Treatment protocol numbers and 5 yr. EFS are depicted.
Adapted from Pui C.H. and Evans W.E., NEJM 1998, 339: 605-15
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involvement, immunophenotype (pro-B ALL, common/pre-B ALL or T-cell) and 
chromosomal abnormalities (BCR-ABL translocation or MLL-gene rearrangement). 
However, the most important risk factors that are associated with a poor outcome 
are: (1) a poor early response to initial prednisone treatment as defi ned by the 
BFM (Berlin-Frankfurt-Munster) study group (in vivo prednisone response) and 
(2) a poor response to the initial multi-chemotherapy regimen, as determined 
by the level of detectable minimal residual disease (MRD). These two clinical 
response parameters and the absence or presence of a BCR-ABL translocation or 
rearranged MLL-gene in the leukemic cells are nowadays used to stratify patients 
into standard, medium and high risk groups. Another important risk factor is the 
in vitro response to prednisolone, as measured using a total cell kill assay. In 
vitro prednisolone resistance is an important adverse risk factor that can even 
identify patients with an unfavorable long-term clinical outcome despite the fact 
that these patients initially had a good in vivo response to prednisone.
   Knowing that in vitro and in vivo prednisone resistance is such an important 
risk factor for adverse outcome, it is important to understand the mechanisms 
underlying prednisone (glucocorticoid) resistance in childhood ALL. However, not 
much is known about these mechanisms. Chapter 2 reviews the literature on 
this topic and the chapters 3 to 7 describe the research project undertaken 
to study the mechanisms involved in prednisone resistance in childhood ALL. In 
chapter 3 we describe the study testing whether polymorphisms or mutations of 
the glucocorticoid receptor gene are related to prednisone sensitivity. The study 
described in chapter 4 analyses whether the expression level of the glucocorticoid 
receptor and its splice variants are related to prednisone sensitivity. In chapter 5 
we study a possible relationship between prednisone sensitivity and the regulation 
of the glucocorticoid receptor upon prednisolone exposition. In chapter 6 we 
tested the hypothesis that expression levels of the (co)chaperone molecules, 
needed by the glucocorticoid receptor to bind glucocorticoids, are related to 
prednisone sensitivity. In chapter 7 we describe a study looking for genes and 
transcription pathways regulated upon prednisolone exposure. The results of the 
different studies are summarized and discussed in the chapters 8 (English) and 
9 (Dutch), including suggestions for further research.
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Chapter 2
Molecular determinants of glucocorticoid sensitivity 
and resistance in acute lymphoblastic leukemia
Leukemia, 2003; 17: 17-25
Wim J.E. Tissing, Jules P.P. Meijerink, Monique L. den Boer, Rob Pieters
University Hospital Rotterdam / Sophia Children’s Hospital, Department of 
Paediatric Oncology/Hematology
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ABSTRACT
Glucocorticoids (GCs) are probably the most important drugs in the treatment 
of ALL. Despite the extensive use of GCs for many years, little is known about 
the molecular mechanisms of sensitivity and resistance. This review summarizes 
the knowledge on GC cytotoxicity in leukemia. The relevance of polymorphisms, 
splice variants and the number and regulation of the GC receptor is discussed. The 
role of multidrug resistance proteins, glutathione and glutathione S-transferase is 
evaluated, as well as the infl uence of the different heat-shock chaperone (HSP-90 
and -70) and co-chaperone proteins (BAG-1 and others) which form a complex 
together with the GC receptor. At last the transactivation and transrepression (via 
NF-κB and AP-1 binding) of a wide range of genes (like c-myc) which initiates the 
fi nal apoptosis pathway are discussed. Finally, suggestions for future directions of 
research in ALL patients are given.
INTRODUCTION
Glucocorticoids (GCs) are involved in many biological processes, including 
metabolism, development, differentiation, immunity, reproduction and neural 
activity. The diverse actions of GCs have led to their use as therapeutic agents 
in the treatment of many diseases. GCs can act anti-proliferative in specifi c 
cell types, which is the reason why GCs are used in immunosuppressive, anti-
infl ammatory and oncolytic therapy. The effect on lymphoid cells is dramatic and 
includes the induction of G1 cell cycle arrest and apoptosis. In newly diagnosed 
acute lymphoblastic leukemia (ALL), prednisone and dexamethasone have 
signifi cant antileukemic effect in the majority of children.1 Although GCs are 
the most important drugs used in the treatment of ALL for more than 50 years, 
the molecular basis of GC sensitivity and resistance remains largely unknown. 
Understanding of the molecular mechanisms related to GC cytotoxicity is crucial 
for understanding a major part of treatment success or failure in childhood ALL and 
is crucial for the exploration of possibilities to modulate GC resistance. This review 
summarizes the current knowledge on molecular determinants of glucocorticoid 
sensitivity and resistance in ALL.
Clinical aspects of glucocorticoid sensitivity
Glucocorticoid sensitivity is a major prognostic factor in childhood ALL. In BFM 
glucocorticoid resistance in ALL
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trials blast count after 7 days of monotherapy with prednisone (including one 
intrathecal dose of methotrexate) was shown to be a strong and independent 
prognostic factor.1-3 Subgroups with a poor prognosis like infants, T-ALL patients 
and patients with a Philadelphia chromosome positive ALL, more often show a 
poor clinical response to prednisone.2, 4, 5 In vitro resistance to glucocorticoids at 
initial diagnosis is related to an unfavorable event free survival in childhood ALL 
as well.6-9 Leukemic cells from the risk groups associated with a poor prognosis 
(T-ALL, proB-ALL, infant ALL) are relatively in vitro resistant to prednisolone.10 
Leukemic cells from adults with ALL, who have an unfavorable outcome as 
compared with children, are more resistant to GCs in vitro too.11, 12 Leukemic cells 
of patients with relapsed ALL are 300 fold more in vitro resistant to prednisolone 
than the cells taken at diagnosis: in paired initial / relapse samples resistance to 
GCs is increased in the majority of patients at the time of relapse compared to 
initial diagnosis.13
The glucocorticoid receptor gene and activation by glucocorticoids 
The glucocorticoid receptor gene (GR) is located on chromosome 5 (5q31) and 
consists of 9 exons encoding for 3 characteristic domains of the protein.14 (Figure 
1) The N-terminal region contains a transactivation domain (AF-1) that is involved 
in transcriptional activation of target genes.15 An internal DNA binding domain 
consisting of two highly conserved “zinc fi ngers” is crucial for the binding to 
the Glucocorticoid Response Elements (GRE) sequence. This domain contains 
a nuclear localization signal (NLS1). The fi rst zinc fi nger (exon 3) encodes for 
domains necessary for binding NF-κB and AP-116 and is therefore important for 
Figure 1 Schematic overview of the GR gene
The GR gene, localized on chromosome 5, consists of 9 coding exons. The functional parts 
of the receptor are indicated. 
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the transrepression mode of the receptor. The second zinc fi nger domain (exon 
4) encodes for receptor dimerisation and GRE mediated transactivation.17-20 The 
C-terminal part of the protein contains the ligand binding domain that also binds 
heat shock proteins (hsp) and is involved in receptor dimerisation. This domain 
contains a second nuclear localization signal (NLS2) and transcription activation 
(AF-2) site.15, 19 The two transactivation domains (AF-1 and AF-2) interact with 
other nuclear proteins such as CBP (CREB binding protein) and P300 that are 
important for stabilization and activation of the transcription initiation complex in 
the promoters of glucocorticoid responsive genes.21 GCs enter the cell by passive 
diffusion and bind to the GR, which is located in the cytoplasm as a homodimer. 
(Figure 2) 
Figure 2. Model of GC induced apoptosis in leukemic cells
Glucocorticoids (GC) enter the cell by passive transport, and bind to the glucocorticoid receptor (GR). 
The unbound GR forms heterocomplexes consisting of heat-shock chaperone molecules HSP-90 and 70, 
co-chaperone molecules HSP-40, HOP (p60), P23 and immunophillins FKBp52 and CYP40, required for 
optimal confi guration of the GR to be able to bind GC. As a homodimer the GC-GR complex translocates 
to the nucleus. There it interacts with either a GRE (consensus sequence (GGT ACA NNN TGT TCT) of 
a target gene (transactivation), or it interacts with other transcription factors such as AP-1 and NF-κB 
(transrepression). Both processes may fi nally result in the induction of cell death (apoptosis). NF-κB is 
kept in the cytoplasm in a complex with IκBα. Upon dissociation it can translocate to the nucleus.
glucocorticoid resistance in ALL
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The GR belongs to the nuclear hormone receptor superfamily, and is highly 
homologous to the mineralocorticoid, progesterone and androgen receptor. Binding 
of GCs to the GR triggers the dissociation of proteins bound to the receptor such 
as HSPs and BAG-1.22 This discloses and activates the nuclear localization signal 
(NLS) domains of the receptor. The GC-GR complex then translocates to the nucleus 
as a homodimer, where it can interact with GRE’s (consensus sequence GGT ACA 
NNN TGT TCT).23 These are located in promoter regions of GC-responsive genes, 
leading to transcriptional activation or inactivation of these genes (the latter hardly 
ever occurs).24 The GC-GR complex can also directly interact with transcription 
factors like activating protein-1 (AP-1) or nuclear factor κB (NF-κB), by forming 
transrepression complexes. The formation of these complexes represses the 
transcriptional activity of both the GR, AP-1 and NF-κB.25 Both transactivation (via 
GRE-binding) and transrepression (via interaction with AP-1 or NF-κB) processes 
can induce apoptosis of GC-sensitive cells, but it is yet unknown if one or both are 
important in ALL.16, 26-30
MOLECULAR MECHANISMS OF SENSITIVITY AND RESISTANCE IN 
LEUKEMIC CELLS
Number of glucocorticoid receptors
The relationship between the number of GRs per cell and the response to GCs in 
patients with ALL has been subject of many studies, as reviewed earlier.31 Most 
authors report a signifi cant correlation between low numbers of receptor per cell 
and a higher rate of induction failure or relapse. However, a high receptor number 
does not necessarily predict a good response to a GC containing regimen. All 
studies about GR numbers used dexamethasone binding assays in which only 
functional receptors are measured (i.e. probably the α- and the γ-isoform -see 
below). 
In contrast to basal expression levels of the receptor, upregulation of the number 
of GRs upon GC exposure may be more important for GC induced apoptosis. In non-
lymphoid cell lines and in peripheral blood mononuclear cells of children with auto-
immune disorders, with no apoptotic response upon GC exposure, a decrease in 
GR mRNA expression and receptor number was observed after exposure to GCs.32-
37 Contrary to the down-regulation in those non-lymphoid cell lines, upregulation 
of the GR upon GC exposure is reported in leukemic and lymphoid cell lines. 
In the leukemic T-cell line CCRF-CEM an upregulation of GR mRNA was shown 
in the fi rst few hours after exposure to GCs.38 Ramdas et al. showed that the 
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basal level of GR expression is inadequate to mediate GC-induced apoptosis in a 
leukemic human T cell line 6TG1.1.39 An increase in GR number by autoregulation 
is required to induce apoptosis in these cells. Recently, Breslin et al. studied the 
hypothesis that activation of different promoters of the GR gene may regulate the 
expression of GR under the infl uence of GCs in different tissues.40 Exon 1A3 mRNA 
(one of at least fi ve transcripts from three different promoters) is expressed most 
abundantly in hematological cancer cell lines that are sensitive to GC-induced 
apoptosis. Furthermore, GC exposure causes upregulation of exon 1A3-containing 
GR transcripts in (hematological) CEM-C7 cells. 
No data exist proving the hypothesis that leukemic cells that are sensitive to 
GCs are able to upregulate their receptor number more pronounced than resistant 
leukemic cells. 
Membrane bound receptor
Whereas the GR is generally described as a cytosolic receptor, Gametchu et al. 
described a membrane bound variant (mGR).41 The expression of the mGR is 
reported to be cell cycle regulated in the CCRF-CEM cell line. The highest expression 
is found during the late S-G2/M phase when the cells are most sensitive to the 
apoptotic effect of GC. The mGR expression varied among leukemic patients, 
whereas no mGR was found in the membrane of lymphocytes of healthy individuals, 
the latter being highly resistant to GC.41, 42 In a pilot study no correlation was 
found between the expression of mGR and in vitro sensitivity to GCs in childhood 
ALL samples. (B. Gametchu, personal communication)
Polymorphisms / somatic mutations of the glucocorticoid receptor gene
A number of endocrinological glucocorticoid resistance syndromes has been 
described that are associated with genetic mutations in the GR.43-47 (A genetic 
mutation is defi ned as an inheritable germline mutation present in a limited number of 
individuals (most commonly within a family) and associated with a higher risk to develop a 
malignancy (e.g. Li Fraumeni syndrome). A polymorphism is defi ned as an inheritable genetic 
germline variant of a single locus (most frequently a single nucleotide variation) that is present 
in at least 1% of the population. The opposite of polymorphisms are somatic mutations 
that are associated with a specifi c type of disease, and thereby restricted to the malignant 
cells only.) These mutations result in a lower number of functional receptors and 
interfere with GC binding or transactivational capacity. Besides genetic mutations, 
several polymorphisms have been described. Although most polymorphisms do 
glucocorticoid resistance in ALL
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not effect receptor function48, 49, one polymorphism has been described which is 
associated with increased sensitivity to GC. This N363S polymorphism is present 
in 3-6% of the population.49-51 Table 1 summarizes the literature references on 
polymorphisms and mutations in the GR as found in healthy individuals, a patient 
with childhood ALL and patients with a glucocorticoid resistance syndrome. 
The role of polymorphisms or somatic mutations in the GR in relation to GC 
cytotoxicity in childhood leukemia is largely unknown. Hillmann et al. showed that 
the GC-resistant CCRF-CEM cell line contains one GR allele with the L753F mutation. 
Analysis of the original biopsy material also revealed the same mutation, but in a 
substantial lower frequency than expected, concordant with the hypothesis that 
this mutation was only limited to a leukemic subclone.52
The different mutations can cause a decreased sensitivity to GCs in various ways. 
Decreased sensitivity to GCs may be related to the location of the mutation (N-
terminal, DNA-binding region or ligand binding region) or to the preferential 
degradation of mutated GRs. The GR transcript can be truncated by a mutation, 
which introduces a premature stop codon, resulting in loss of mRNA expression 
and loss of GR number and might be associated with decreased GC sensitivity.43, 52 
Table 1. Polymorphisms and mutations in the glucocorticoid receptor gene described in 
healthy individuals, a patient with childhood ALL and patients with a glucocorticoid resistance 
syndrome. 
Identity of genetic alteration GC Sensitivity Reference
Polymorphisms  
Healthy individuals  
    Double mutation codon 22+23  Unchanged 49
     F29L Unchanged 48
     L112F Unchanged 48
     D233N Unchanged 48
     K293K Unchanged 48
     N363S Increased 43
     Intron 3: 46 nucleotides upstream from exon 4: G – C Unchanged 49               
    Intron 4: 16 nucleotides upstream from exon 5: G – C Unchanged 49             
     D677D Unchanged 48
     Codon 766: Asn – Asn Unchanged 48/49
  
Somatic Mutations  
Patients with GC resistance syndromes  
     R477H Decreased 47
     I559N Decreased 45
     Δ4 deletion 3’ boundary exon 6  Decreased 43
     D641V Decreased 44
     G679S Decreased 47
     V729I Decreased 46
Patient with ALL  
     L753F Decreased 52/120
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Other mutations may interfere with correct splicing of the pre-mRNA transcript. 
Karl et al. showed that a 4-basepair deletion on the boundary of exon 6 resulted 
in the absence of transcripts of that allele, so GR is only encoded by one wild type 
allele.43
The relevance of polymorphisms and genetic or somatic mutations in the GR 
gene for GC sensitivity and prognosis in childhood leukemia is subject of ongoing 
studies in our laboratory53 and of others. If these genetic aberrations are important 
for the cellular response to GCs, the presence of these polymorphisms / mutations 
can be used to identify patients at risk for a poor response to GC treatment. 
In addition, patients with a polymorphism that is associated with increased GC 
sensitivity like the N363S polymorphism may benefi t from GCs in their treatment. 
However, these patients may also suffer from severe side effects, such as Cushing 
syndrome, overweight, depression and avascular necrosis of bone. These patients 
may still have an excellent prognosis when treated with a lower dosage of GCs. 
Splice variants of the glucocorticoid receptor
Five different splice variants of the GR gene have been described, formed by 
alternative splicing, i.e. the α, β, γ, GR-P and GR-A isoform. (see Figure 3)
1 - The α isoform is the functional receptor and is encoded for by exon 2 to 9α.54 
It is located in the cytoplasm in the absence of GCs, but migrates to the nucleus 
upon GC binding.55 The only study of the relation between splice variants and 
GC sensitivity in leukemic patients was done by Longui et al.56 They described a 
reduced GR-α expression in the leukemic blasts of 13 ALL patients in comparison 
with EBV transformed lymphocytes of 9 normal controls. The GR-α expression 
was lowest in T-ALL samples and no concomitant decrease in GR-β expression 
in the leukemic cells of these patients was observed. The authors suggest that 
decreased GR-α expression levels may explain the lower GC sensitivity in T-ALL 
patients as compared to pre B-ALL. However, the proof for the relevance of the 
alpha splice variant is indirect as there was no in vitro or in vivo assessment of GC 
sensitivity and the patient number is very small.
2 - The β isoform is the result of alternative splicing of exon 9β instead of 9α, 
resulting in 15 unique C-terminal amino acids. As a consequence, GR-β cannot bind 
GCs.54 At mRNA level, GR-β expression is 0.2 – 1 % of the total GR expression.57, 
58 Strikingly, at protein level, the data are controversial and vary from levels 
comparable to mRNA levels59, 60 to 5-fold higher expression levels compared with 
GR-α.61 The reason for these confl icting data might be lack of specifi city of the 
glucocorticoid resistance in ALL
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antibodies used in these studies.
The β isoform might have a dominant negative effect over the α isoform. Vottero 
et al. and Carlstedt-Duke reviewed the controversial data on this hypothesis.62, 63 
In GC resistant asthma patients, Leung et al found a relatively higher expression 
of GR-β in peripheral blood mononuclear cells as compared to GC sensitive asthma 
patients64, but Gagliardo et al could not confi rm this.65 Transfection studies in cell 
lines are also inconclusive. Some transfection studies showed a negative effect of 
GR-β over GR-α66, 67, whereas others did not.60, 68, 69 As the expression level of the 
beta isoform is very low compared to the alpha isoform, the relevance of the beta 
expression or resistance in childhood leukemia is unlikely. 
3 - The γ isoform has only recently been described.70 In this splice variant exon 4 
is alternatively spliced to exon 3 thereby including 3 basepairs of the intron region 
resulting in an additional arginine residue. This isoform is expressed at 3.8 – 8.7 
% of total GR mRNA in different human tissues but it is unknown whether this 
variant is a separate splice variant or part of the α, β and GR-P isoforms.70, 71 Ray 
et al. reported that the biological activity of the γ isoform is reduced to 50% of the 
wild-type receptor.72 Gerdes et al. reported preliminary results showing a possible 
role for the γ isoform in poor prednisone response in childhood ALL.71
Figure 3. The glucocorticoid receptor gene and 5 different splice variants
Chapter 2
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4 - The GR-P isoform is encoded by exons 2-7 plus several basepairs from 
the subsequent intron region.73 As a consequence, this isoform lacks the ligand 
binding domain and therefore can not bind GCs. The GR-P transcripts account for 
up to 10-20% of total GR mRNA, but has been reported to be upregulated in a 
small group of hematological malignancies (ALL, non Hodgkin’s lymphoma and 
multiple myeloma, up to 54 % of total GR mRNA).57, 74-76 In a study of De Lange et 
al.77, transfection of GR-P receptor increased the activity of the GR-α receptor. In 
the same study no relation was found between sensitivity to GCs and the ratios of 
the GR-α, GR-β and GR-P isoforms in a group of multiple myeloma patients.
5 - The fi fth variant described, the GR-A variant, has an excision of exons 5,6 
and 7, resulting in the in frame juxtaposition of exon 8 to 4. No further information 
is known about the expression levels and function of this variant.73
Studying the relevance of the alpha, beta and hGR-P splice variants for GC 
sensitivity in childhood ALL, preliminary data from our laboratory did not show 
a relation between mRNA levels of the 3 splice variants and in vivo or in vitro 
sensitivity to GC. Further work is needed to defi ne the importance of the different 
splice variants in relation to GC sensitivity in ALL and to delineate the mechanisms 
of GR mRNA splicing regulation. 
Phosphorylation of the GR
Phosphorylation of receptors is a general regulation mechanism in cells. 
Phosphorylation of the GR modulates the GR function as reviewed by Bodwell.78 The 
phosphorylation rate is maximal in the S-phase and enhances the transactivating 
and transrepressing activities of the GR. Furthermore the GR is destabilized by 
phosphorylation, resulting in a shorter half-life of the protein. The clinical relevance 
of phosphorylation of the GR is unknown.  
Multidrug resistance and GC sensitivity
P-glycoprotein (P-GP) is a drug-effl ux pump responsible for multidrug resistance 
(MDR) and encoded for by the mdr-1 gene. In a murine thymoma cell line it was 
shown that increased resistance to dexamethasone was linked to an increased 
expression of the mdr1 gene of P-GP. Verapamil, able to restore intracellular 
drug concentrations by blocking the drug-effl ux pump, was able to increase the 
intracellular level of dexamethasone.79, 80 However, contrary to these cell line 
studies, in a report on leukemic cells of 112 children with ALL no correlation 
between GC resistance in vitro and the expression or function of P-GP activity 
glucocorticoid resistance in ALL
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was found.81 Furthermore, functional P-GP activity was not related to in vivo 
prednisone response in a group of 90 ALL patients.82 In addition, GC-resistance 
was not associated with an increased expression of other multi-drug resistance 
related proteins such as major vault protein / lung resistance protein (MVP/LRP) 
and multidrug resistance-associated protein (MRP-1).81
Glutathione and Glutathione S-transferase
Increased glutathione (GSH) levels and glutathione S-transferase (GST) 
overexpression contribute to resistance to various cytostatic drugs. Maung et al. 
found in their study of 21 newly diagnosed patients a positive correlation between 
GSH level and prednisolone resistance.83 However, in a recent report concerning 
62 newly diagnosed children with ALL, this relationship was not confi rmed.84 In 
addition, the expression levels of GST (α, μ and π-class) were not related to in 
vitro prednisolone sensitivity in childhood ALL.85 Anderer et al. reported about the 
implication of polymorphisms in the GST genes for GC sensitivity in childhood ALL. 
In a case-control study of 45 in vivo poor responders and 90 good responders there 
was a reduced risk of prednisone poor response in patients with a homozygous 
deletion of GSTT1 (null genotype), although this difference was not statistically 
signifi cant (p=0.071).86 
Protein interaction with the GR in the cytoplasm
The unstimulated GR is sequestered within the cytoplasm where it can bind into 
heterocomplexes consisting of heat-shock chaperone molecules HSP-90 and -70, 
co-chaperone molecules HSP-40, HOP (p60), P23 and immunophillins FKBP-51 
and CYP40. This heterocomplex is required for optimal confi guration of the GR 
to be able to bind GC.87 In a recent study only HSP 90 and HSP 70 were found 
to be required and suffi cient for GC binding to its receptor.88 A second function of 
the heat shock chaperone molecules is the formation of a heterocomplex with the 
GR, which induces a conformational change in the ligand binding domain of the 
receptor, facilitating nuclear transport of the receptor.22 Kojika et al reported about 
the adverse effect of an abnormal expression of HSP-90 and a low expression of 
HSP-70 on sensitivity to GCs in 2 human leukemic cell lines.89 
Another co-chaperone molecule BAG-1 (also named RAP46) has been found to 
bind to many different proteins including HSP-70. This molecule may inhibit HSP-
70 function and GR-heterocomplex formation thereby interfering with GC binding 
to the GR.90, 91 It is tempting to speculate that overexpression of BAG-1 may result 
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in cellular resistance to GCs, and indeed, cell line studies have demonstrated 
that BAG-1 overexpression resulted in cellular resistance against dexamethasone-
induced apoptosis.91 
Glucocorticoids and transcription factors
Besides from binding to the GRE, the GC-GR complex is thought to recruit NF-κB and 
AP-1 into a transrepression complex. This complex abrogates the transcriptional 
activation of GR, NF-κB and AP-1 responsive genes (transrepression). Besides 
physical interaction and inactivation of NF-κB by the GC-GR complex92, NF-κB is 
also inactivated by a second mechanism. Since IκBα is a GR responsive gene93-
95, induction of GR leads to higher levels of IκBα which decreases the level of 
nuclear NF-κB. Enhanced expression of IκBα may thereby stimulate GC induced 
apoptosis.95, 96 Contrary to this hypothesis are the results from Heck et al. who 
conclude by dimerisation-defective GR mutant studies that IκBα synthesis is 
neither required nor suffi cient for the hormone mediated downregulation of NF-κB 
activity.97 The only study using leukemic blasts from children with ALL did not fi nd 
a difference in NF-κB level in a group of 42 good and poor in vivo responders to 
GC.98
The second transcription factor interacting with the GR is AP-1, a heterodimer 
of Fos and Jun proteins. Since AP-1 target genes are involved in cell proliferation, 
a reduction of functional AP-1 levels may therefore facilitate apoptosis. However, 
Bailey et al.99 did not fi nd a relationship between levels of AP-1 and in vitro 
prednisolone resistance in ALL and chronic lymphoid leukemia blasts, nor between 
prednisolone-induced changes in AP-1 binding activity and in vitro GC resistance. 
It is not known whether GR-GRE binding, GR interactions with transcription 
factors or both are of importance for GC induced apoptosis in ALL. Favoring the 
importance of GR-GRE binding are the results from a study by Reichardt et al.27 
An A458T point mutation was introduced in the DNA binding region of mouse 
GR, thereby abolishing GRE-binding. T-lymphocytes of these mutant mice were 
refractory to dexamethasone induced apoptosis, whereas wild type T-lymphocytes 
were highly sensitive to dexamethasone induce apoptosis. 
Genes regulated by GC
Many genes have been proposed to be regulated by GCs.29, 100 GCs induce G0/G1 
arrest of proliferating cells. This suggests that GCs reduce the expression of genes 
related to cell growth and cell viability. An important gene is c-myc, a known target 
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gene of NF-κB. Thompson et al. concluded in their studies that negative regulation 
of c-myc expression is a signifi cant step in the initial pathway leading to apoptosis 
in the CEM cell line.101-103 Non-obese diabetic (NOD) mice with T lymphocytes 
that are resistant to GC-inducible apoptosis show no reduced c-myc levels after 
GCs.104 On the contrary, Löffl er et al reported that c-myc downregulation may not 
be critical for induction of cell-death by GCs since transfection of c-myc into the 
human T-cell leukemia CEM cell line increased the sensitivity to GC-induced cell 
death.105 One of the reasons for these confl icting results may be that increased c-
myc expression sensitizes the CEM cell line to apoptosis in a similar way as shown 
by Evan et al, i.e. an enhancement of apoptosis by enforced c-myc expression 
following growth-factor deprivation which was observed in the absence of GC 
treatment.106
Another important target gene, known to be upregulated in a leukemic cell line 
but downregulated in cells not undergoing apoptosis after GC exposure is the GR 
gene itself.29, 32-34, 36, 39 The relationship between the potency to upregulate the 
GR number and sensitivity to GCs in ALL is currently subject of study in different 
laboratories. 
Using gene chip arrays, many genes have been found to be regulated under 
the infl uence of GCs. A notable cluster of the repressed genes seemed to be 
of importance for the processes of transcription, mRNA splicing and protein 
synthesis. It remains to be shown whether GCs trigger one specifi c apoptotic 
pathway or that a more general suppression of macromolecule synthesis is the 
cause of apoptosis.107 
Apoptosis pathway
GCs induce apoptosis in leukemic cells. Both transactivation of GRE containing 
genes and transrepression of genes via NF-κB and AP-1 interactions are probably 
essential.16, 26-28, 30 In rat thymocytes it was shown that glucocorticoid induced 
apoptosis depends on protein synthesis and de novo gene expression.108 There 
are two major apoptosis pathways: the fi rst starting with a disruption of the 
mitochondrial membrane potential and cytochrome c and SMAC release after 
which caspase 9 is activated. This pathway seems to be important for GC induced 
apoptosis.109, 110 The second apoptosis pathway, induced by membrane death 
receptors as reviewed by Ashkenzi111, is not critically involved in the apoptotic 
response to GC.29 Brady et al. showed that the apoptosis pathway induced by GCs 
is p53 independent.112
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An important protein studied in relation to GC induced cell death is the anti-
apoptotic protein BCL-2. Hartmann et al. reported that BCL-2 protects cells 
against GC induced apoptosis in the human T-ALL cell line (CCRF-CEM) up to 
48 hours. But, when cultured for another 24 hours, these cells undergo massive 
apoptosis. BCL-2 did not affect GC-mediated growth arrest, thereby separating 
the anti-proliferative effect of GCs from the apoptosis-inducing effect.113 This was 
confi rmed in other studies, as GCs in the presence of high levels of BCL-2 only has 
an anti-proliferative effect but not an apoptotic effect, while in the presence of low 
BCL-2 expression, GC induced apoptosis.114-116 In different studies in children with 
ALL, expression of BCL-2 or BCL-2 family members could not be related to in vitro 
or in vivo GC resistance.117-119 Contrary to the hypothesis that the anti-apoptotic 
protein BCL-2 is related to resistance to GC induced apoptosis are the results of 
a study of 110 patients treated according to the German BFM protocols. Good 
responders to initial prednisone therapy had higher BCL-2 expression levels than 
poor responders. The authors speculate that this high BCL-2 expression might be 
due to upregulation by cytokines, which may also be important for in vivo tumor 
cell survival.82 BCL-2 is a member of a larger BCL-2 family, consisting of both pro- 
as well as anti-apoptotic proteins. It could be that not the absolute expression of 
BCL-2, but the ratio of all family members are the most important in determining 
sensitivity to GC treatment in ALL. However Salomons et al. did not fi nd a 
relation between the BAX:BCL-2 ratio and the response to 7 days monotherapy of 
prednisone in a group of 76 patients.117 
The fi nal activation of caspases seems to be a downstream effector event during 
apoptosis, but the trigger for this pathway remains unknown. Kofl er suggests that 
the continuous repression of metabolic pathways by GR upregulation contributes to 
cell cycle arrest, ultimately leading to apoptosis. Particularly critical in this context 
might be the downregulation of lactate dehydrogenase, an enzyme controlling 
glycolysis in cells.29, 38 The suggestion that metabolic events have to take place 
before the induction of apoptosis may be in accordance with our own unpublished 
in vitro observations that induction of apoptosis in ALL cells derived from patients 
is a late event starting only after 24 hours from the start of exposure to GCs. 
PERSPECTIVES
In vivo and in vitro sensitivity to GCs are associated with prognosis in childhood 
ALL. This review has summarized the knowledge on genes and proteins that 
regulate GC sensitivity. Future studies should focus on polymorphisms, splice 
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variants and regulation of the GR, on transcription factors activated or repressed 
by GCs and on downstream molecules that control the apoptotic cascade. Based 
upon knowledge derived from these studies, strategies to modulate GC resistance 
in ALL can be developed. 
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ABSTRACT
Glucocorticoid (GC) sensitivity is an important prognostic factor in pediatric acute 
lymphoblastic leukemia  (ALL). For its antileukemic effect, GCs bind the intracellular 
GC receptor (GR), subsequently regulating transcription of downstream genes. We 
analyzed whether genetic variations within the GR gene are related to differences 
in the cellular response to GC.
   Methods. In leukemic samples of 57 children, the GR gene was screened for 
nucleotide variations using a PCR - SSCP - sequencing strategy. Data were linked 
to in vivo and in vitro GC resistance. 
   Results. No somatic mutations were detected in the GR gene coding region, but 
six polymorphisms (i.e. ER22/23EK, N363S, Bcl1, intron mutation 16 basepairs 
upstream of exon 5, H588H and N766N) were identifi ed. In 67% of ALL cases 
at least one minor allele of these polymorphisms was detected. Although only 
borderline signifi cant, the incidence for the N363S polymorphism minor allele was 
higher (12% vs. 6%, p=0.06) and for the ER22/23EK minor allele lower (4% vs. 
7.6%, p=0.1) than in a healthy, comparable population. The different genotypes 
of the polymorphisms were not related to prednisone resistance.
   In conclusion, polymorphisms but not somatic mutations in the GR gene coding 
region occur in leukemic blasts of children with ALL. Our data suggest that these 
genetic variations are not a major contributor for differences in cellular response 
to GCs in childhood ALL. The higher incidence of the N363S minor allele and the 
lower incidence of the ER22/23EK minor allele in our ALL population as compared 
to a normal population warrants further research.
INTRODUCTION
Glucocorticoids (GC) are the keystone in the treatment of children with acute 
lymphoblastic leukemia (ALL). In vivo and in vitro GC response are important 
prognostic factors for outcome.1-5
   GCs enter the cell by passive diffusion and bind to the intracellular glucocorticoid 
receptor (GR). The GC-GR complex is translocated to the nucleus, where it 
triggers transactivation as well as transrepression of GC responsive genes. The 
transactivation and/or transrepression of downstream genes fi nally result in the 
induction of programmed cell death (apoptosis). The presence of point mutations 
or particular polymorphisms in the GR gene may lead to an impaired formation of 
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the GC-GR complex or alter the transactivation or transrepression process.
   In the last decade, patients with generalized glucocorticoid resistance syndromes 
were described, which were linked to somatic mutations in the GR gene localized 
within specifi c domains of the GR gene.6-10 (Figure 1A and 1B) Besides somatic 
mutations, polymorphisms within the GR gene have been described in healthy 
populations (Figure 1C), of which some were associated with altered responsiveness 
to GC. The ER22/23EK polymorphism results in decreased sensitivity for GC11, 
whereas two other polymorphisms (N363S and Bcl1) have been associated with an 
increased GC sensitivity as measured with a dexamethasone suppression test (i.e. 
the response of the serum cortisol level upon 1 mg dexamethasone given orally 
the evening before) in asymptomatic healthy adults.12-14 The clinical relevance of 
the increased sensitivity for GCs in relation to the N363S polymorphism remains 
controversial15-19, but the Bcl1 polymorphism has been related to a higher body 
mass index, abdominal obesity and higher systolic blood pressure.12, 20, 21 Besides 
Figure 1. The human glucocorticoid receptor (GR) gene with known mutations 
and polymorphisms 
A. The gene structure of the GR. Known somatic mutations and polymorphisms are indica-
ted with arrows. The C643R and L753F are mutations found in ALL cell lines.
B. Location of functional domains within the GR gene.
C. Polymorphisms in the GR as reported in the literature.
Polymorphism Incidence in healthy  GC sensitivity Phenotype reference
 population
ER22/23EK 7.4% heterozygote decreased Better metabolic health profi le  11, 22
N363S 6% heterozygote increased Possibly related to overweight  13, 15-18, 38  
   and higher body mass index
Bcl1 48% heterozygote increased Increased (abdominal) obesity, 12, 20, 35-37
 12% homozygote  increased body mass index 
   and increased blood pressure.   
Intron mutation 46 basepairs  2.5% heterozygote Normal  18, 22 
upstream from exon 4
Intron mutation 16 basepairs  42% heterozygote Normal  18, 22
upstream from exon 5 10% homozygote   
N766N 22.5% heterozygote Normal  18, 22
 2.5% homozygote  
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these three polymorphisms, various other polymorphisms have been described 
with no or an unknown relationship to GC responsiveness.19, 22-24
   Till date, primary ALL patient cells have not been analyzed for genetic variations 
in the GR gene which might explain GC resistance. Somatic mutations in the GR 
gene have been described in 2 ALL cell lines (L753F, C643R) for which it is yet 
unclear whether these mutations alter the response to GC.25-28 
   In the present study we analyzed the incidence of genetic variations in the coding 
region of the GR gene and the Bcl1 restriction site and whether such genetic 
variations are related to in vitro or in vivo GC resistance in childhood ALL.
MATERIALS & METHODS
Patients. All patients were treated according to the DCOG (Dutch Childhood 
Oncology Group) ALL treatment protocols 7 and 8. These protocols start with 7 
days monotherapy of prednisone and 1 intrathecal dose of MTX. The prednisone 
response was determined on day 8: prednisone good response (PGR) is defi ned as 
less than 1000 leukemic blasts/μl peripheral blood and prednisone poor response 
(PPR) as ≥ 1000 blasts/μl.29 Patient material was taken prior to initial therapy. To 
differentiate between (leukemic) somatic mutations and polymorphisms, we also 
collected normal peripheral blood mononuclear cells (PBMCs) of the same patients 
at complete remission (CR). The study has been approved by the medical ethical 
committee of the Erasmus Medical Center Rotterdam and written informed consent 
was obtained from the patients and/or their parents or guardians as appropriate. 
The mononuclear cell fraction was separated by Lymphoprep density gradient 
centrifugation (density 1.077 g/ml, Nycomed Pharma, Oslo, Norway), and, when 
necessary, non-leukemic cells were depleted by immunomagnetic beads to purify 
the samples to more than 90% of leukemic cells.
   DNA isolation. DNA was extracted using Trizol reagent (Gibco BRL, Life 
Technologies), according to the protocol supplied by the manufacturer with some 
modifi cations. An additional protein degradation step was performed, using 
Proteinase K (1 mg/ml). DNA was purifi ed in 2 separate steps. In the fi rst step 
DNA was precipitated using 0.5M NaCl, 60 μg of glycogen and 2.5 volumes of 70% 
EtOH followed by an additional phenol extraction and a chloroform extraction. In 
the second purifi cation step, DNA was precipitated in 0.3M NaAc and 2 volumes 
of EtOH 70%.
   PCR amplifi cation. 100 ng genomic DNA was used to amplify the GR gene using 
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the primers as described in Table 1. The Genebank Accession Number AC091925 
was used as reference GR sequence to which sequence variations were compared. 
For the exons 3 to 9-alpha, the primers were located in intronic DNA directly 
fl anking these exons. Since exon 2 was too large to be amplifi ed in a single 
PCR, fi ve overlapping PCRs were developed to cover exon 2 (Table 1A). The PCR 
reaction was performed in 100 μl 1 x PCR buffer II (Applied Biosystems, Foster 
City, CA, USA), 3 mM MgCl2 (except 2-4: 1.5 mM), 250 nM of dNTPs (10 μmol/μl, 
Amersham Biosciences, Freiburg, Germany), 3 Units of AmpliTaq Gold (5U/μl, 
Applied Biosystems, Foster City, CA, USA), 100 ng DNA and 400 nM of the forward 
and reverse primers. Prior to amplifi cation, DNA was denatured and AmpliTaq 
Gold activated for 9 minutes at 950C, followed by 40 cycles of denaturation at 950C 
for 30 sec, annealing at 550C (except 2-4: 590C) for 30 sec, extension at 720C for 
60 sec and a fi nal period of extension at 720C for 10 min. 
   SSCP analysis. Ten μl of PCR product was mixed with 45 μl denaturating loading 
buffer. For optimal resolution, two loading buffers were used separately: buffer 
I contained 50 mM of NaOH, 1 mM of EDTA and 0.05% bromophenol blue, buf-
fer II contained 96% of formamide, 20 mM EDTA and 0.05% bromophenol blue. 
DNA was denatured in buffers I and II by heating for 10 minutes at 500C and 
950C respectively followed by direct cooling on ice. Six μl was loaded on a 12.5% 
polyacrylamide gel (Genegel excel, Amersham Biosciences, Freiburg, Germany). 
The products were separated on a Genephor electrophoresis unit (Amersham Bio-
sciences, Freiburg, Germany) with accompanying bufferstrips (Amersham Biosci-
ences, Freiburg, Germany), using 2 different temperatures for optimal resolution 
(50C and 180C). The DNA fragments were separated for 2 hours at 600V, 25mA 
and 15W. Gels were stained using the PlusOneTM DNA silver staining kit (Amer-
sham Biosciences, Freiburg, Germany).
   Sequencing. PCR products displaying an abnormal migration pattern on SSCP gels 
were sequenced. PCR products were purifi ed using the QIAquick PCR purifi cation 
kit. (Qiagen, Leusden, the Netherlands) The BigDye Terminator V1.1 cycle 
sequencing kit (Applied Biosystems, Foster City, CA, USA) was used according 
to the protocol as provided by the manufacturer. Sequencing primers used were 
the same as used in the PCR reaction (Table 1A), although for some reactions 
separate sequencing primers were developed (Table 1B). The products of the 
sequencing reaction were analyzed using the ABI Prism 310 Genetic Analyzer 
(Applied Biosystems, Foster City, CA, USA).
   Taqman analysis of the Bcl1 polymorphism. Since the Bcl1 polymorphism is 
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Table 1.
A. Primers used for PCR / SSCP analysis* 
Exon 2-1 fw 5’ GAT TCG GAG TTA ACT AAA AG 3’ §
 rev 5’ ATC CCA GGT CAT TTC CCA TC 3’
Exon 2-2 fw 5’ CCA AGC AGC GAA GAC TTT TG 3’ §
 rev 5’ TAC CTG GGG ACC CAG AAG AA 3’ §
 
Exon 2-3 fw  5’ CCA CAG AGA AGG AGT TTC CA 3’ § 
 rev  5’ TTG CCT GAC AGT AAA CTG TG 3’ §
  
Exon 2-4 fw  5’ CCA GTA ATG TAA CAC TGC CCC 3’ §
 rev  5’ TTC GAC CAG GGA AGT TCA GA 3’ §
Exon 2-5 fw  5’ AGT ACC TCT GGA GGA CAG AT 3’
 rev  5’ GTC CAT TCT TAA GAA ACA GG 3’
Exon 3 fw  5’ AGT TCA CTG TGA GCA TTC TG 3’ §
 rev  5’ CGT GAG AAA TAA AAC CAA GT 3’ §
Exon 4 fw  5’ CAC CGG AAA CAA AGA CA 3’ §
 rev  5’ TTT TAT TGG GCA GTA ACA TT 3’ §
Exon 5 fw  5’ GAA TAA ACT GTG TAG CGC AG 3’
 rev  5’ TAG TCC CCA GAA CTA AGA GA 3’
Exon 6 fw  5’ GAT CTT CTG AAG AGT GTT GC 3’ §
 rev  5’ GGG AAA ATG ACA CAC ATA CA 3’ §
Exon 7 fw  5’ GAA AGT TCT CCA AAA TTC TG 3’ §
 rev  5’ TTG GTG TCA CTT ACT GTG CC 3’ §
Exon 8 fw  5’ GAC ACA GTG AGA CCC TAT CT 3’ §
 rev  5’ CAC CAA CAT CCA CAA ACT GG 3’ §
Exon 9 alpha fw  5’ GGA ATT CCA GTG AGA TTG GT 3’ §
 rev  5’ TAT AAA CCA CAT GTA GTG CG 3’ §
B. Primers used for the sequencing reaction which are different from the primers 
in Table 1A
Exon 2-1 fw  5’ GAT TCG GAG TTA ACT AAA AG 3’ (conform 1A)
 rev  5’ TAC TGA GCC TTT TGG AAA AT 3’
Exon 2-5 fw  5’ GGA GGA CAG ATG TAC CAC TA 3’
 rev  5’ AAA AGC ACA TGA ATC TTT AGA G 3’
Exon 5 fw  5’ CTC CCA TCT TAA TAG TTT TAG AA 3’
 rev  5’ TGG GCT CAC GAT GAT ATA A 3’
C. Primers and probe used for Taqman analysis*
Bcl1  fw 5’ GCT CAC AGG GTT CTT GCC ATA 3’
 rev 5’ TTG CAC CAT GTT GAC ACC AAT 3’
 probe 5’ -FAM-TCT GCT GAT CAA TCT 3’
  5’ -VIC-TCT GCT GAT GAA TCT 3’
§ Primers used for both the PCR reaction and the sequencing reaction.
* Some of the primers and the probe have been described before22.
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located in intron 2 and is not covered by exonic PCR amplifi cation reactions, 
a separate analysis was performed as described previously.12 Briefl y, an allelic 
discrimination using Taqman-chemistry on an ABI PRISM 7700 sequence detector 
(Applied Biosystems, Foster City, CA, USA) was used. Primers and probe as 
depicted in Table 1C were used at concentrations of 400 nmol/l and 50 nmol/l 
respectively. 
   MTT assay. In vitro drug cytotoxicity was assessed with the MTT assay as 
described earlier.2,5,30 Briefl y, patient blasts were cultured with or without 
prednisolone disodiumphosphate in a concentration range between 0.06 and 250 
μg/ml. At day 4 MTT is added, which can only be reduced into formazan by viable 
cells. The reduced product was measured spectrophotometrically at 562 nm. The 
leukemic cell survival is calculated by: (OD drug treated well / OD control wells 
without drug) x 100%. The LC50 value represents the concentration of the drug 
at which 50% of the cells are killed and is used as measure of in vitro drug 
cytotoxicity. In vitro prednisolone sensitivity was determined as sensitive (LC50 ≤ 
0.1 μg/ml), intermediate (LC50 0.1 – 150 μg/ml) or resistant (LC50 ≥ 150 μg/ml), 
as has previously been described to be of prognostic value.5, 31 
   Statistics. The Chi-square test for trend and the Mann-Whitney test with 
correction for tied ranks were used to test for a difference in genotype distribution 
for the polymorphisms between the study population and a healthy population. A 
logistic regression analysis, the Chi-square test for trend and the Mann-Whitney 
test with correction for tied ranks were used to test for a relationship between 
the different genotypes (wildtype, heterozygous or homozygous) and in vivo or 
in vitro GC resistance. A power analysis yields that, with a p-value < 0.05, a 
standardized difference of 0.85 in such a study (42 in vivo prednisone sensitive and 
15 resistant patients) is detected with 0.8 power. This allows to draw conclusions 
on large differences between sensitive and resistant patients, which is what we 
expect when GC resistance is determined by genetic variations. The probability 
of event-free survival (pEFS) was calculated using the Kaplan-Meier method and 
a correlation between different genotypes and pEFS was analyzed using the log-
rank test. 
RESULTS
In this study, 57 children with ALL were included for which in vitro and/or in vivo 
response towards GCs was known. Patient characteristics are given in Table 2. To 
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study whether in vitro or in vivo resistance correlated with the presence of genetic 
variations within the GR gene, we developed a PCR/SSCP strategy. The sensitivity 
of the SSCP technique varies between 80-95% using a single SSCP condition.32 In 
the current study, we used 2 denaturating conditions and 2 temperature conditions 
to further improve the level of detection of genetic variations in the GR. PCR 
products showing an abnormal migration pattern on SSCP gel were sequenced. 
To check for the sensitivity and specifi city of the assay, control samples with 
known genotype (wildtype, heterozygote and homozygote) for the polymorphisms 
N363S, the intron mutation upstream of exon 5 and N766N, obtained from a 
previous study of J.W. Koper and co-workers22, were analyzed and successfully 
distinguished (data not shown). Secondly, in all PCR products with an aberrant 
SSCP pattern, a nucleotide variation was found after DNA sequencing. Thirdly, 50 
PCR products with a normal SSCP pattern were sequenced, showing only wildtype 
alleles. 
   Each genetic variation had its specifi c denaturating buffer and temperature at 
which the resolution was most optimal (for example, N363S was detected with 
both buffer I and II at 18°C, whereas the intron mutation 16 basepairs upstream 
of exon 5 only was detected with buffer II at 5°C). Figure 2A shows an example 
of the SSCP pattern for the PCR products of exon 5 for 13 patients. The results 
Table 2. Patient characteristics of the study population.
  N (%)
Gender Male 34 (60)
 Female 23 (40)
Age 0-1 years 5 (9)
 1-10 years 40 (70)
 ≥ 10 years 12 (21)
WBC < 50000 /µl 34 (60)
 ≥ 50000 /µl 23 (40)
Immunophenotype Common / pre-B ALL 45 (79)
 T-ALL 11 (19)
 pro-B ALL 1 (2)
In vivo prednisone response * Prednisone good response 42 (74)
 Prednisone poor response  15 (26)
In vitro prednisolone response **  Sensitive 16 (40)
 Intermediate 16 (40)
 Resistant  8 (20)
* The in vivo prednisone response is determined on day 8 after 7 days of monotherapy of 
prednisone and one intrathecal dose of MTX: Prednisone good response (PGR) is defi ned 
as less than 1000 leukemic blasts/μl peripheral blood and prednisone poor response (PPR) 
as ≥ 1000 blasts/μl.29 
** In vitro prednisolone response was determined using the MTT assay as sensitive (LC50 
≤ 0.1 μg/ml), intermediate (LC50 0.1 – 150 μg/ml) or resistant (LC50 ≥ 150 g/ml).5, 31 
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of the sequencing procedure for 3 of these patients (wildtype, heterozygote and 
homozygote) are shown in Figure 2B. 
   SSCP analysis of the coding exons 2-9 of the GR gene in 57 patients and 
subsequent DNA sequencing of aberrant SSCP patterns resulted into the detection 
of 6 different genetic variations. These 6 genetic variations were all identifi ed 
as previously known polymorphisms, namely ER22/23EK, N363S, Bcl1, intron 
mutation 16 basepairs upstream of exon 5, H588H and N766N (Table 3). No 
previously unknown mutations were detected in these patients. In 55% of the 
patients with one or more GR gene sequence alterations in the ALL blasts, normal 
Figure 2. Example of the detection of mutations in the GR by PCR-SSCP and 
sequence analysis
A. SSCP pattern of exon 5 of 12 patient samples, representing an intron mutation 16 
basepairs upstream of exon 5: wildtype in lanes 2, 3, 7, 11, 12, heterozygous in lanes 1, 4, 
5, 6, 9, 10, 13 and a homozygous mutation in lane 8.
B. Sequence analysis of 3 patients for the site of the intron mutation 16 basepairs upstream of 
exon 5. 1- represents a wildtype patient, 2- represents a heterozygous and 3- a homozygous 
patient.
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mononuclear cells at the time of complete remission were available for further 
analysis. In all cases, the sequence alterations such as found in the leukemic 
blasts were also present in these non-malignant cells, indicating that these 
alterations were indeed polymorphisms. The genotype distribution was consistent 
with a Hardy-Weinberg equilibrium.
   In 38 out of 57 patients (67%), at least one minor allele of the polymorphisms 
was found. In 2 patients we found 4 minor alleles, in 11 patients 3 minor alleles, 
in 9 patients 2 minor alleles and in 16 patients 1 minor allele. In 19 patients 
no abnormalities were detected. (Note that only 53 patients were screened 
for the Bcl1 polymorphism and only 56 patients were screened for the N766N 
polymorphism.)
   The genotype distribution of the polymorphisms in our cohort was comparable 
to the incidence as reported in literature, except for the N363S and ER22/23EK 
polymorphisms. (Figure 1C) The minor allele of the N363S polymorphism was 
observed in a higher percentage of ALL patients (12%) and the minor allele of 
ER22/23EK polymorphism was found in only 4% of the patients as compared 
to 6% and 7.4% respectively in the normal, healthy population from the same 
topographical region. The test to compare the incidence in the study population 
and the incidence as reported in the literature yielded borderline signifi cance 
(p=0.06 and p=0.1).
   The relationship between the polymorphisms and in vivo and in vitro GC resistance 
is shown in Table 3. We analyzed a possible relationship between GC resistance 
versus wildtype, heterozygote and homozygote as well as a possible relationship 
between GC resistance versus wildtype and one minor allele (i.e. heterozygote or 
homozygote). None of the polymorphisms appeared to be correlated with in vivo 
prednisone response (N=57) nor with in vitro prednisolone resistance (N=40) 
(Table 3). The presence of 2 minor alleles in one patient (e.g. N363S and Bcl1) did 
not correlate with in vivo or in vitro GC resistance as well. 
In this small cohort of 57 patients, we did not fi nd an association between the 
presence of polymorphisms and event-free survival (data not shown).
DISCUSSION
Glucocorticoids are important drugs in the multi-drug treatment protocols for 
children with ALL. The in vivo prednisone response as used in the BFM studies 
has been found to be one of the strongest prognostic factors for therapy outcome 
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in childhood ALL.1, 29, 33 The in vitro prednisolone sensitivity of untreated leukemic 
cells, as determined by the MTT assay, is a strong risk factor for outcome as well, 
and can predict the occurrence of a relapse even within the group of patients with 
a good in vivo prednisone response.2, 4, 5, 31 
   To induce apoptosis in GC sensitive cells, GCs has to bind the intracellular GR. This 
results in transactivation and/or transrepression of GC responding genes, which 
eventually results in apoptosis in GC sensitive patients. Although GC resistance is 
an important cause of treatment failure, little is known about possible mechanisms 
of GC resistance in childhood ALL.34 In this study we tested the hypothesis that GC 
resistance is the result of genetic variations within the GR gene which might alter 
the GC-binding capacity or transactivation or transrepression of GC responding 
genes.
   Analysis of the coding region of the GR gene for sequence alterations in 57 
patients revealed six different genetic variations. These genetic variations were 
identical to previously reported polymorphisms (i.e. ER22/23EK, N363S, Bcl1, 
intron mutation 16 basepairs upstream of exon 5, H588H and N766N). (Figure 
1) No somatic mutations, which might result in altered GC sensitivity, were found 
in these 57 ALL cases. In 2 studies somatic mutations were found in cell lines 
from ALL patients. A L753F somatic mutation was shown to be present in CCRF-
CEM cells and original ALL cells from which the cell line was established.27 As 
the L753F somatic mutation was found in both the GC sensitive and resistant 
clones of the CCRF-CEM cell line, it probably has no correlation with GC sensitivity. 
25, 26 The C643R somatic mutation was found in a cell line established from a 
Japanese patient with ALL (P30/OHK). It is not clear whether this mutation was 
also present in the original cells or that it was acquired during tissue culture. 
Transfection studies showed that the C643R allele had no transcriptional 
activity but no evidence was given whether this mutation was related to GC 
resistance in ALL cells.28 All together these data suggest that somatic mutations 
do not occur frequently and can not explain resistance to GCs in pediatric ALL. 
   In contrast to somatic mutations, we detected several polymorphisms of the GR 
gene in children with ALL. Confi rmation of the same genetic variations in normal 
peripheral blood mononuclear cells obtained during clinical remission confi rmed 
that the variations indeed were polymorphisms. Other polymorphisms of the GR 
gene as reported in the literature with a low incidence were not detected in our 
population, nor did we detect any so far unreported genetic variations. Although 
we can not exclude that these polymorphisms with low incidence were missed by 
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our PCR/SSCP, we had optimized our strategy to achieve a high detection limit, so 
it is reasonable to assume that these low incidence polymorphisms were absent 
in our population.
   The genotype distribution of the polymorphisms Bcl1, N766N and the intron 
mutation upstream of exon 5 was the same as reported in the literature. However, 
the minor allele of the ER22/23EK polymorphism was found in a lower percentage 
than in a healthy population of the same ethnicity (4% versus 7.4% respectively), 
whereas the minor allele of N363S was found in a higher percentage as compared 
to the healthy population of the same ethnicity (12% versus 6% respectively).13 
Since the number of patients in our study is small and no statistical signifi cance 
was reached (p=0.1 and p=0.06 respectively), the altered frequency of both 
polymorphisms warrants further evaluation in a larger cohort of patients. The 
minor allele of the H588H polymorphism was found in one of our patients. It was 
reported before in cell lines that originate from four Japanese individuals.24 In a 
previous Dutch study including a large healthy population, this polymorphism was 
not reported.22
   In the literature, the clinically most relevant polymorphism of the GR gene is the 
Bcl1 polymorphism.12 Previously, it was detected with a restriction fragment length 
polymorphism-based technique, but recently the exact mutation was found to be 
a C/G single nucleotide polymorphism in intron 2, 646 basepairs downstream from 
exon 2, for which a specifi c real-time PCR approach has been developed.12, 35 It 
is associated with increased response to a dexamethasone suppression test and 
with increased (abdominal) obesity, body mass index and blood pressure.20, 36, 37 
However, in our population the Bcl1 polymorphism was not correlated with in vivo 
or in vitro GC sensitivity. Also for the other fi ve polymorphisms no correlation with 
in vivo or in vitro GC response was found.
   In conclusion, polymorphisms but not somatic mutations in the coding region of 
the GR gene occur in leukemic blasts of children with ALL. Our data suggest that 
genetic variations in the GR gene are not a major contributor for differences in 
cellular response to GCs in childhood ALL
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ABSTRACT
Background and objectives. Resistance to glucocorticoid (GC) induced apoptosis 
is a major prognostic factor in the treatment of acute lymphoblastic leukaemia 
(ALL). We analyzed whether expression levels of the functional glucocorticoid 
receptor splice variant GR-alpha or the GR-beta and GR-P splice variants (not able 
to bind GC) are related to GC resistance in childhood ALL. 
Design and methods. 54 patients were analyzed. Within this group, each of 21 
in vitro prednisolone sensitive cases was matched (for age, immunophenotype 
and leukocyte count at diagnosis) to a resistant case. Expression levels were 
determined by quantitative real-time RT-PCR.
Results. GR-alpha represented 71% of total GR expression, GR-beta 0.1% and 
GR-P 29%. The mRNA expression level of the functional GR-alpha splice variant 
was signifi cantly lower in resistant compared to sensitive patients. The expression 
of GR-beta and GR-P as percentage of total GR expression did not differ. Validation 
on a cell line panel showed that GR-alpha mRNA expression levels closely matched 
GR-protein levels. 
Interpretation and conclusions. A low GR-alpha expression level is associated with 
in vitro GC resistance. GR-beta and GR-P expression are not related to in vitro GC 
resistance. The low expression level of GR-beta makes it questionable whether 
GR-beta has any biological relevance.
INTRODUCTION 
Glucocorticoids (GC) are widely used in the treatment of childhood acute 
lymphoblastic leukemia (ALL). In the majority of children newly diagnosed with 
ALL, GCs such as prednisone and dexamethasone have a signifi cant antileukemic 
effect.1 In the BFM (Berlin-Frankfurt-Münster) treatment protocols, the in vivo 
response to prednisone was consistently found to be one of the strongest prognostic 
factors for treatment outcome.2, 3 Like the in vivo response to prednisone, the 
in vitro response to prednisolone is correlated with outcome as well, even for 
patients who demonstrated a good in vivo prednisone response.4-6 Although GCs 
have been used in the treatment of ALL for decades, little is known about the 
mechanisms of GC resistance.
 GCs exert their function by binding to the glucocorticoid receptor (GR). The 
importance of the number of receptors in relation to resistance to GCs in childhood 
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ALL has been subject of many dexamethasone binding studies, which have 
suggested a correlation between low GR numbers and a higher rate of induction 
failure or relapse. Paradoxically, a high GR expression was not necessarily 
associated with a good clinical response, indicating that other factors may also 
underlie GC resistance.7 In contrast, two recent studies concluded that GR protein 
expression levels were not related to in vivo and in vitro GC resistance in childhood 
ALL. 8, 9 
 Besides encoding for the functional GR-alpha splice variant, the human GR gene 
also encodes for various splice variants which are unable to bind GCs.10 (Figure 
1A) Whereas some studies reported a dominant negative effect of the GR-beta 
product on GR-alpha function, others did not fi nd any effect for this splice variant.11-
14 Functional analysis of the GR-P splice variant in cell lines has suggested that the 
GR-P product enhances GR-alpha function.15, 16 In the only study so far relating GR 
splice variants to GC resistance in childhood ALL, GR-alpha (protein and mRNA) 
and GR-beta (mRNA) expression levels were not related to in vitro GC resistance 
(13 sensitive and 9 resistant, non-matched patients).9
 There have been different hypotheses on how GR splice variants may induce 
GC resistance, as these splice variants might interfere with the transactivation 
or transrepression function of GR-alpha as recently reviewed.17 Upon GC binding, 
the liganded GR-alpha is transported into the nucleus. As a homodimer, it may 
regulate the transcription of various genes by binding to glucocorticoid responsive 
element (GRE) sequences located in the promoter region of GC responsive genes.18 
GR splice variants other than GR-alpha may impair GR-mediated transactivation 
by forming heterodimers with a GR-alpha, thereby inhibiting GRE binding and 
transactivation.11 Apart from binding GRE, GR-alpha can interact with transcription 
factors such as NF-κB or AP-1, thereby inducing transrepression of the NF-κB or 
AP-1 responsive genes.19 One might speculate that a competition between GR-
beta, GR-P, and GR-alpha for this binding may lower transrepressive activity.11 
 In the present study we tested the hypothesis that the mRNA expression of 
GR-alpha or the splice variants GR-beta or GR-P are correlated to in vitro GC 
resistance in primary patient samples of children with ALL. 
MATERIALS / METHODS
 Patients. The total group comprised 54 children with ALL at initial diagnosis. 
Within this group 21 patients with leukemic cells in vitro sensitive to prednisolone 
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were matched each to 21 in vitro resistant leukemic patients (matched group). 
Matching criteria were age category, immunophenotype and WBC (white blood cell 
count) category at diagnosis. Age categories were defi ned as 1-9 years and ≥10 
years, and WBC categories were determined as <50 x 103/µl and ≥50 x 103/µl.
 Patient material was obtained at diagnosis, after written informed consent 
was obtained from the patients or their parents. The mononuclear cell fraction 
was collected by Lymphoprep density gradient centrifugation (density 1.077g/
m3, Nycomed Pharma, Oslo, Norway), followed by immunodepletion of non-
leukemic cells using immunomagnetic beads for samples with blast-counts below 
90 percent.20 Cells were cryopreserved in RPMI 1640 medium (Gibco, Paisly, 
UK) supplemented with 10% dimethyl sulfoxide (Merck, Darmstadt, Germany) 
and 20% fetal calf serum (Gibco, Paisly, UK) and stored in liquid nitrogen. No 
differences have been observed in GR-alpha, GR-beta and GR-P expression levels 
between fresh and cryopreserved patient material (data not shown). 
 Isolation of mRNA and cDNA synthesis. Total RNA was extracted using the Trizol 
method (Gibco BRL, Life Technologies), with minor modifi cations to the protocol 
supplied by the manufacturer to improve RNA quality.21 RNA pellets were dissolved 
in 20 μl TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH = 8.0), and quantifi ed 
spectrophotometrically. cDNA was synthesized following standard procedures.22
 Quantitative real-time RT-PCR. The mRNA levels of GR-alpha, GR-beta, GR-P 
and one endogenous reference gene, i.e. GAPDH, were measured by quantitative 
real-time RT-PCR based on Taqman-chemistry using an ABI PRISM 7700 sequence 
detector (Applied Biosystems, Foster City, CA, USA). PCR products were detected 
by a dual-fl uorescent non-extendable probe containing a 6-carboxyfl uorescein 
(FAM) reporter-group and a 6-carboxytetramethylrhodamine (TAMRA) quencher-
group for all reactions. Primer and probe combinations were designed using Oligo 
6.0 primer analysis software (Molecular Biology Insights, Cascade, CO, USA), 
and purchased from Eurogentec (Belgium). (Figure 1A) GenBank accession codes 
Table 1. Primer and probe combinations used for the quantitative real time RT-
PCR. 
Gene Forward primer Probe  Reverse primer
GR-alpha 5’-TGT TTT GCT CCT  5’ FAM-TGA CTC TAC CCT GCA TGT  5’-TCG GGG AAT TCA ATA CTC A-3’
          GAT CTG A-3’                         ACG AC-TAMRA 3’                               
GR-beta Idem Idem 5’-TGA GCG CCA AGA TTG T-3’
GR-P Idem Idem 5’-CCT TTG TTT CTA GGC CTT C-3’
GAPDH 5’-GTC GGA GTC AAC  5’ FAM-TCA ACT ACA TGG TTT ACA  5’-AAGCTT CCC GTT CTC AG –3’
                 GGA TT-3’                   TGT TCC AA-TAMRA 3’
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used for the human GR gene were AC091925 and AC0126634, and ACJ04038 for 
the GAPDH gene (Table 1). All primers and probes had melting temperatures of 
65±1oC and 75±1oC respectively (nearest neighbor method at a salt concentration 
of 303 mM of Na+ equivalent and 300 nM of primer concentration). The PCR 
reactions were very specifi c, showing only one single PCR product on gel. (Figure 
2) Amplifi cation effi ciency was over 95% for all reactions (data not shown). One 
hundred nanograms of genomic DNA served as a negative control and did not 
show any amplifi cation for any of these reactions, confi rming the specifi city of 
these reactions for mRNA detection. Forty nanograms of patient sample cDNA 
was amplifi ed in duplo in the presence of 300 nM forward and reverse primers, 
50 nM of probe, 200 μM dNTPs, 4 mM MgCl2 and 1.25 U of AmpliTaq
TM gold DNA 
polymerase in Taqman buffer A (Applied Biosystems) in a total volume of 50 μl. 
Samples were heated for 10 min at 95°C, and amplifi ed for 40 cycles of 15 sec 
at 95°C and 60 sec at 60°C. A cDNA serial dilution derived from a mRNA mixture 
from several leukemic cell lines was amplifi ed on each plate, and served as a 
Figure 1. Schematic overview of the glucocorticoid receptor gene and GR-alpha, 
GR-beta and GR-P splice variants 
(A) The location of the primers and probes are indicated. 1: forward primer for GR-alpha, 
GR-beta and GR-P, 2: probe for GR-alpha, GR-beta and GR-P , 3: GR-alpha reverse 
primer, 4: GR-beta reverse primer, 5: GR-P reverse primer. 
(B) The functional domains of the GR.
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Figure 2. Verifi cation of the real-time PCR products
The specifi city of the real-time PCR and site of the amplifi cation products was verifi ed by 
loading equal amounts of each PCR reaction on a 1% agarose gel. Shown is the EtBr staining 
profi le for GR-alpha (lane 2), GR-beta (lane 3), GR-P (lane 4), GAPDH (lane 5) and the 100 
bp ladder as a marker (lane 1).
positive control to verify the amplifi cation effi ciency within each experiment.21 For 
each patient sample, the average Ct-value from two independent experiments 
was used to calculate the expression levels of GR-alpha, GR-beta and GR-P mRNA 
relative to the GAPDH expression level using the comparative Ct method23 using 
the equation: 
relative expression = 2-[Ct(target)-Ct(GAPDH)] x 103 (arbitrary units, AU)
The multiplication factor 103 was chosen to get whole fi gures.
 Correlation mRNA and protein levels. 9 cell lines were used to control for a 
possible correlation between GR mRNA and protein expression levels. (K562, 
MUV2, Molt, RS4-11, HL60, SEMK4, Jurkat, TOM-1 and REH) The mRNA levels 
were measured as described above. Protein extraction and western blot was 
performed using standard procedures. The polyclonal anti-human GR antibody 
PA1-511A (Affi nity Bioreagents, Golden, CO, USA) was used as primary antibody 
in a 1:500 dilution. As secondary antibody we used a peroxidase-conjugated 
goat-anti-rabbit antibody (DAKO, Glostrup, Denmark). The blot was developed by 
SuperSignal West Femto Maximum chemiluminescent substrate (Peirce, Rockford, 
IL, USA), and captured using the ChemiGenius bio imaging system (Syngene, 
Cambridge, UK) and GeneSnap imaging capture software. Band intensities were 
quantifi ed using Genetools analysis software. Like all commercially available anti-
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GR-antibodies, the PA1-511A antibody recognizes all GR splice variants. GR-alpha 
protein (94 kD) represents the major quantity of total GR expression and was 
determined by evaluating the band at 94 kD on Western blot (normalized to Beta-
actin); GR-P protein was determined at 66 kD and normalized to Beta-actin. GR-
beta protein (97 kD) could not be visualized on Western Blot. 
 MTT-assay. In vitro drug cytotoxicity was assessed with the MTT 
assay.4, 6, 24 Briefl y, patient leukemic blasts were cultured with or without 
prednisolone disodiumphosphate in a concentration range between 0.06 and 250 
μg/ml. At day four, MTT is added which can only be reduced into formazan by 
viable cells. The reduced product was quantifi ed spectrophotometrically at 562 
nm. The leukemic cell survival is calculated by:
(OD drug treated well / OD control wells without drug) x 100%.
The LC50 value represents the concentration of the drug at which 50% of the 
cells are killed; it is used as measure of in vitro drug cytotoxicity. Leukemic cells 
having LC50 values lower than 0.1 μg/ml were assigned in vitro glucocorticoid 
sensitive, samples having LC50 values exceeding 150 μg/ml were considered in 
vitro resistant, such as previously defi ned.6, 25
 Statistical methods. The non-parametric Mann-Whitney U test was used for 
analyzing the unmatched patients. To analyze the results from the matched patient 
samples, the Wilcoxon’s rank test for matched samples was used. The Spearman’s 
rank-correlation test was used to test the correlation between mRNA and protein 
expression. A p-value ≤0.05 was considered statistically signifi cant (two-tailed 
tested). 
RESULTS 
In this study it was tested whether in vitro prednisolone resistance in childhood 
ALL was due to variations in the expression of the functional GR (GR-alpha). 
Furthermore, the expression levels of two alternatively spliced variants GR-beta 
and GR-P were also investigated. Patient characteristics are depicted in table 2.
First, we analyzed the GR mRNA expression levels in the total group (N=54). 
GR-alpha had the highest mRNA expression level with a median expression of 
21.8 AU relative to GAPDH (P25-P75: 11.5-33.8 AU), comprising 71% of the total 
GR expression (sum of the 3 splice variants GR-alpha, GR-beta and GR-P). GR-P 
mRNA expression was much lower at 29% of total GR expression and a median 
expression relative to GAPDH of 8.6 AU (P25-P75: 3.6-14.0 AU). At 0.1%, the GR-
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Table 2. Patient characteristics of the total group and the matched group.
 Total group Matched group
 N=54 N=42
   In vitro  In vitro 
   sensitive resistant
Gender Male 28 10 10
 Female 26 11 11
Age at diagnosis 1 - 9 years 36 15 15
 > 10 years 26 11 11
Initial WBC < 50000 /µl 32 14 14
 ≥ 50000 /µl 22 7 7
Immunophenotype pre-B / common ALL 40 15 15
 T-ALL 14 6 6
In vitro prednisolone  Sensitive  29
sensitivity resistant 25
Figure 3. Expression of the splice variants GR-alpha, GR-beta and GR-P in relation 
to GC resistance in the total group
(A) Distribution of GR-alpha mRNA expression relative to GAPDH in sensitive (N=29) and 
resistant (N=25) patients. There is a signifi cant difference between the sensitive and 
resistant patients (p=0.002). Horizontal lines indicate the median value. • indicates 
individual patients.
(B) GR-alpha, GR-beta and GR-P expression as percentage of the total GR expression in 
relation to GC resistance. There is no signifi cant difference between in vitro sensitive 
and resistant patients. Note that the relative expression of GR-beta is very low at 
approximately 0.1%.
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beta mRNA expression level was very low, near the border of the detection limit 
by quantitative real-time RT-PCR. 
In the total study group, the expression of the functional GR-alpha splice variant 
was signifi cantly lower in the resistant patients than in the sensitive patients (1.95 
fold, p=0.002, Figure 3A). The mRNA expression level of GR-beta and GR-P was 
signifi cantly lower as well (p=0.022 and 0.001 respectively). As a percentage of 
total GR expression, the mRNA expression levels of GR-alpha, GR-beta and GR-P 
did not differ between sensitive and resistant patients. (Figure 3B)
 Using a matched pair analysis comparing 21 in vitro prednisolone sensitive 
patients with 21 in vitro resistant patients, matched for age, immunophenotype 
and WBC, GR-alpha mRNA expression levels were again signifi cantly lower in 
the resistant patients than in the sensitive patients (1.6 fold, p=0.039, Figure 
4). Again, GR-beta and GR-P had a signifi cantly lower expression level in the in 
vitro resistant patients. (p=0.05 and 0.011 respectively) As in the total group, 
the percentages of GR-alpha, GR-beta and GR-P were not different between the 
matched sensitive and resistant patients (data not shown).
To analyze whether the mRNA expression of GR-alpha correlated with the protein 
level, we measured mRNA levels in combination with protein levels of cell lysates 
(obtained at the same time) of nine hematological cell lines. As shown in Figure 5, 
GR-alpha mRNA levels correlated strongly with GR-alpha protein level (rho 0.950, 
p<0.01). A similar trend was observed for GR-P, but due to the low expression 
level, this did not reach statistical signifi cance. The expression level of GR-beta is 
so low, that it could not be visualized on Western Blot. 
Figure 4. Expression of GR-alpha in relation to GC resistance in the matched 
group
GR-alpha mRNA expression relative to GAPDH for 42 matched patients. There is a signifi cant 
difference between the in vitro sensitive and resistant patients (p=0.04). Lines connect the 
matched patients. • indicates individual patients.
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Figure 5. The correlation between GR-alpha protein and mRNA levels
DISCUSSION
As GC resistance is a poor prognostic factor in the treatment of childhood ALL1, 4-6, 
25, 26, it is important to increase our understanding of the mechanisms involved in 
GR resistance.
 In the present study, we analyzed whether the expression level of the functional 
GR-alpha and the expression levels of GR-beta and GR-P are related to GC 
resistance in primary ALL patient cells. With GR-alpha being the predominant 
splice variant at 71% of total GR expression, GR-beta being expressed at only 
0.1% and GR-P at 29%, the expression levels are comparable with those reported 
in the literature.9, 16, 27, 28 Since the mRNA expression of GR-beta was very low, it is 
questionable whether this splice variant has any biological relevance in leukemia 
at all.
 GR-alpha mRNA expression levels were almost twice as low in the in vitro 
resistant patients as in the sensitive patients, both in the total group (1.95 fold, 
N=54) and in the matched group (1.6 fold, N=42). This is in concordance with 
earlier studies, in which a lower dexamethasone capacity was correlated with a 
poor response to single-agent glucocorticoid therapy.7 In our study we proved for 
the fi rst time that this correlation is due to a lower expression of the functional 
GR-alpha, instead of increased expression of GR-beta and GR-P, competing with 
the functional GR-alpha for GRE or transcription factor binding, as proposed in 
the literature.11-16 In contrast to our fi ndings, one recent study showed that a low 
level of GR-alpha (the functional splice variant) is not related to GC resistance.9 
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However, this study included only a small number of patients, which may explain 
the negative results.
 Although the expression of GR-beta and GR-P was signifi cantly lower in the in 
vitro resistant versus the sensitive patients, the expression as percentage of total 
GR expression was not different between these patients. So, GR-beta and GR-P are 
not likely to play a clinically relevant role in GC resistance in childhood ALL. This 
is in agreement with the fact that these splice variants have a truncated ligand-
binding domain and are not able to bind GC. (Figure 1B) However, it contrasts 
earlier hypotheses, that these truncated splice variants interfere with the function 
of GR-alpha either by forming heterodimers with this splice variant, disabling its 
function, or by competing with GR-alpha to bind NF-κB and AP-1.11-14
 Because our data represented mRNA level measurements only, we also analyzed 
the correlation between mRNA and GR protein expression. Since not enough 
patient material for mRNA and protein measurements was available from the same 
patients, we used nine different cell lines instead, covering a wide dynamic range 
of GR expression levels. We showed a strong and signifi cant correlation between 
GR-alpha mRNA and protein expression in 9 cell lines. This is in concordance with 
the results from other studies in a variety of human cells and in ALL patients.9, 
13 A general GR antibody was used to quantify the protein level of GR-alpha and 
GR-P using Western blotting at 94 and 66 kD respectively. Although there are 
commercially available antibodies specifi c for GR-alpha and GR-beta, we doubt 
the specifi city of these antibodies, because another splice variant, GR-gamma, 
which has a three basepair insertion between exon 3 and 4 will always be included 
in the quantifi cation of GR-alpha, GR-beta and GR-P as well (both on mRNA and 
protein level).8, 29 In a pilot study there were suggestions that the expression of 
GR-gamma might be related to GC resistance in childhood ALL.30 In another more 
recent study, a signifi cantly higher GR-gamma expression in 8 in vitro resistant 
patients was found as compared to 7 in vitro sensitive patients.9 As the median 
expression level of GR-gamma was found to be only 2.8% of total GR expression, 
it may be hard to envision how this splice variant might infl uence GC sensitivity. 
The relevance of this splice variant for GC sensitivity needs further research.
 In conclusion, low GR-alpha expression levels are related to in vitro prednisolone 
resistance in childhood ALL. Expression levels of GR-beta and GR-P do not 
contribute to in vitro prednisolone resistance in childhood ALL.
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ABSTRACT
Glucocorticoid (GC) resistance is an adverse prognostic factor in childhood ALL, but 
little is known about causes of GC resistance. Upregulation of the glucocorticoid 
receptor (GR) has been suggested as an essential step to the induction of apoptosis 
in leukemic cells. In this study we investigated whether base-line mRNA expression 
levels of the fi ve different GR promoters transcripts (1A1, 1A2, 1A3, 1B and 1C) or 
differences in the degree of regulation of the GR or GR promoter transcripts upon 
GC exposure are related to GC resistance.
Material & Methods. mRNA levels of the fi ve GR promoter transcripts and of 
the GR were measured by quantitative real-time RT-PCR (Taqman) technology in 
primary ALL cells prior to and after 3, 8 and 24 hours of prednisolone exposure.
Results. The base-line and GC-induced expression levels of the fi ve different GR 
promoter transcripts did not correlate with GC resistance. GC exposure induced an 
upregulation of the GR in ALL cells, which is opposite to what is found in tissues 
in which GC exposure does not induce apoptosis. However, in GC resistant ALL 
samples no defective upregulation of the GR was detected. 
Conclusion. GR expression is induced upon GC exposure in primary ALL patient 
samples. However, GC resistance in childhood ALL can not be attributed to 
differences in GR promoter usage (at base-line and upon GC exposure), nor to 
an inability of resistant cells to upregulate the expression of the GR upon GC 
exposure.
INTRODUCTION
Glucocorticoids (GC) like prednisolone and dexamethasone have been used in 
the treatment of childhood acute lymphoblastic leukemia (ALL) for many years. 
Although poor early prednisone response as determined in the BFM (Berlin-
Frankfurt-Munster) treatment protocols and in vitro cellular resistance to 
prednisolone are important adverse riskfactors in the treatment of childhood ALL1-
3, little is known about causes underlying GC resistance.4, 5 
To induce apoptosis, GCs have to bind to the intracellular GC receptor (GR). 
Most cell types demonstrate a down regulation of the amount of GR upon GC 
exposure6-8, probably as part of a physiological feed-back mechanism.9 In contrast, 
an upregulation of GR mRNA and protein levels has been demonstrated in various 
cell lines of lymphoid leukemias10-12 and has been described to be essential for GC 
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Figure 1. Schematic overview of the different 5’ glucocorticoid receptor transcripts 
derived from the use of 3 different promoters
The GR promoter transcripts 1A, 1B and 1C are alternatively spliced to exon 2.
The locations of the forward primer (), the reverse primer () and the probe 
(°  °) are indicated.
induced apoptosis.13 Hence, resistance towards GCs in patient cells may be caused 
by lack of GR upregulation upon GC exposure.13, 14 
Besides the functional GR-alpha transcript, several other 3’ splice variations of 
the GR have been described that are unable to bind GCs (GR-beta and GR-P). 
These variants retain a normal DNA binding motif and may compete with GR-
alpha for binding to glucocorticoid responsive elements (GREs) of targeted genes 
or with transcription factors interacting with the GR, thereby interfering with GR-
alpha function and causing resistance.15, 16 We have shown before that leukemic 
cells from ALL patients resistant to GCs express less of the functional GR-alpha 
variant17, and that base-line mRNA expression levels of the GR transcripts GR-beta 
and GR-P are not relevant for GC resistance.17, 18
   The GR gene has three different promoters, i.e. 1A, 1B and 1C which results into 
transcripts that include the corresponding exon 1A, 1B and 1C respectively. Since 
exon 1A can be alternatively spliced in 3 variants (1A1, 1A2 and 1A3), in total fi ve 
different 5’ GR transcript variants exist. (Figure 1) These GR promoter transcripts 
are expressed at various levels in different cancer cell lines.19-22 Differential usage 
of these GR promoter transcripts might be responsible for differences in GC 
cytotoxicity in hematological malignancies.19 This is supported by the fact that 
the 1A promoter, but not 1B and 1C, contains a GRE that may enhance GR-1A 
transcript production upon GC exposure.21
In the present study we determined whether resistance to GCs in leukemic cells 
of children with ALL can be explained by altered base-line and / or GC-induced 
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expression of 5’ GR promoter transcripts (1A1, 1A2, 1A3, 1B and 1C) and of the 
3’ GR splice variants (GR-alpha, GR-beta and GR-P). 
MATERIAL & METHODS
Patient samples. Two study populations were included. For the base-line GR 
promoter study, 24 pediatric ALL patients with leukemic blasts in vitro sensitive 
to prednisolone were matched each to a patient with leukemic blasts in vitro 
resistant to prednisolone. Patients were matched according to age (1-9 years 
of age and ≥ 10 years of age), immunophenotype (precursor B-ALL and T-ALL) 
and white blood cell (WBC) count (<50 x 109 / l and ≥ 50 x 109 / l). None of 
the patients had poor prognostic cytogenetic abnormalities like the t(9,22) and 
11q23 (MLL) rearrangements. For the GR regulation study, 22 unmatched patients 
were included. Patient material was obtained prior to initial therapy after written 
informed consent was obtained from the patient and / or their parents according 
to regulations and approval by the local ethical committee. 
Lymphoprep density gradient centrifugation (density 1.077 g/ml, Nucomed 
Pharma, Oslo, Norway) was used to separate the mononuclear cell fraction, and, 
when necessary, immunomagnetic beads were used to deplete non-leukemic 
cells from the samples. All samples therefore contained more than 90% leukemic 
blasts. 
MTT-assay. In vitro drug cytotoxicity was assessed using the MTT assay as 
described earlier.23, 24 Briefl y, patient blasts were cultured with or without 
prednisolone disodiumphosphate in a concentration range of 0.06 to 250 μg/mL. 
At day 4 MTT was added which can be reduced into formazan by viable cells 
only. The reduced product was quantifi ed spectrophotometrically at 562 nm. The 
leukemic cell survival was calculated by: (OD drug treated well / OD control well 
without drug) x 100%. The value of the concentration of the drug at which 50% 
of the cells are killed represents the LC50, which was used as measure of in vitro 
drug cytotoxicity. Leukemic cells having LC50 values lower than 0.1 μg/ml were 
assigned in vitro prednisolone sensitive, samples having LC50 values exceeding 
150 μg/ml were considered in vitro resistant, as previously described to be of 
prognostic value.23, 25
Prednisolone exposure. To study the effect of prednisolone exposure on GR 
mRNA levels in childhood leukemia, leukemic blasts were incubated in culture 
medium as used in the MTT assay, supplemented with 250 μg/ml prednisolone 
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for 3, 8 and 24 hours. In each case, leukemic blasts were incubated as well in 
culture medium without prednisolone as control to discard variations due to other 
mechanisms than prednisolone exposure. 
Isolation of RNA and cDNA synthesis. Total RNA was extracted using the Trizol 
method (Gibco BRL, Life Technologies, Breda, the Netherlands) according to the 
protocol provided by the manufacturer with minor modifi cations to improve RNA 
quality.26 The RNA pellets were dissolved in 20 μl TE-buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH= 8.0) and quantifi ed spectrophotometrically. cDNA was synthesized as 
described before.26 
Quantitative real-time RT-PCR. Levels of mRNA expression of the 3’ GR transcripts 
GR-alpha, GR-beta and GR-P, the 5’ GR promoter transcripts GR-1A1, GR-1A2, 
GR-1A3, GR-1B and GR-1C (i.e. target PCRs) and two endogenous reference 
genes (i.e. GAPDH and RNaseP) were measured by quantitative real-time RT-PCR 
based on Taqman-chemistry using an ABI PRISM 7700 sequence detector (Applied 
Biosystems, Foster City, CA, USA). Specifi c primers and probes were designed 
using GenBank accession codes AC091925 for the human GR gene, AC012634 
and ACJ04038 for the GAPDH gene and X15624 for RNaseP (table 1). All primers 
and probes had melting temperatures of 65±1oC and 75±1oC respectively (nearest 
neighbor method27). The PCR reactions were very specifi c, showing only a single 
PCR product on gel (data not shown). One hundred nanograms of genomic DNA 
served as a negative control and did not result in product amplifi cation for any of 
these reactions, confi rming the specifi city of these reactions for RNA detection. 
Forty nanograms of patient sample cDNA was amplifi ed in duplo in the presence 
of 300 nM forward and reverse primers, 50 nM probe, 200 μM dNTPs, 4 mM 
MgCl2 and 1.25 U of AmpliTaq
TM gold DNA polymerase in Taqman buffer A (Applied 
Biosystems) in a total volume of 50 μl. Samples were heated for 10 min at 95°C 
and amplifi ed in 40 cycles of 15 sec at 95°C and 60 sec at 60°C. A positive control 
was amplifi ed on each plate to verify the amplifi cation effi ciency within each 
experiment.26 The average Ct-value was used to calculate mRNA expression levels 
of the PCR targets relative to the expression level of the two reference genes 
using the comparative Ct method27 using the equation: 
relative expression = 2-[Ct(target)-Ct(reference gene)] x 100.
Statistical methods. The non-parametric Wilcoxon signed rank test for matched 
samples was used to compare GR promoter transcript expression of matched 
sensitive and resistant cases, as well as for the analysis of the GR promoter 
transcript regulation upon prednisolone exposure. To test whether the GR was 
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Table 1. Primers and probes used to discriminate the different 5’ GR-promoter and 
3’ GR transcripts (GR-alpha, GR-beta and GR-P) expression in pediatric ALL.
Primers and probes were designed using AC091925 and AC012634 for the GR gene, 
ACJ04038 for GAPDH and X15624 for RNaseP
GR-1A1  fw 5’-CAC TGG ACC TTA GAA GTT GAT A-3’
  rev 5’-ATA CAG TCC CAT TGA GAG TGA-3’
  probe 5’-(FAM)-CCC TAA GAG GAG GAG CTA CTG AA-(TAMRA)- 3’
GR-1A2  fw 5’-GAA TAG AAA CAG AAA GAG GTT GAT A-3’
  rev 5’-ATA CAG TCC CAT TGA GAG TGA-3’
  probe 5’-(FAM)-CCC TAA GAG GAG GAG CTA CTG AA-(TAMRA)-3’
GR-1A3  fw 5’-AGT GTC TGA GAA GGA AGT TGA TA-3’
  rev 5’-ATA CAG TCC CAT TGA GAG TGA-3’
  probe 5’-(FAM)-CCC TAA GAG GAG GAG CTA CTG AA-(TAMRA)-3’
GR-1B  fw 5’ –GGC CCA AAT TGA TAT TCA-3’
  rev 5’-ATA CAG TCC CAT TGA GAG TGA-3’
  probe 5’-(FAM)-CCC TAA GAG GAG GAG CTA CTG AA-(TAMRA)-3’
GR-1C  fw 5’-CTG CTC CTT CTG CGT TC-3’
  rev 5’-ATA CAG TCC CAT TGA GAG TGA-3’
  probe 5’-(FAM)-CCC TAA GAG GAG GAG CTA CTG AA-(TAMRA)-3’
GR-alpha fw 5’-TGT TTT GCT CCT GAT CTG A-3’
  Rev  5’-TCG GGG AAT TCA ATA CTC A-3’
  Probe  5’-(FAM)-TGA CTC TAC CCT GCA TGT ACG AC-(TAMRA)-3’
GR-beta fw 5’-TGT TTT GCT CCT GAT CTG A-3’
  Rev  5’-TGA GCG CCA AGA TTG T-3’
  Probe  5’-(FAM)-TGA CTC TAC CCT GCA TGT ACG AC-(TAMRA)-3’
GR-P fw 5’-TGT TTT GCT CCT GAT CTG A-3’
  Rev  5’-CCT TTG TTT CTA GGC CTT C-3’
  Probe  5’-(FAM)-TGA CTC TAC CCT GCA TGT ACG AC-(TAMRA)-3’
GAPDH Fw  5’-GTC GGA GTC AAC GGA TT-3’
  Rev  5’-AAGCTT CCC GTT CTC AG -3’
  Probe  5’-(FAM)-TCA ACT ACA TGG TTT ACA TGT TCC AA-(TAMRA)-3’
RNaseP  Fw 5’-TTG GGA AGG TCT GAG ACT A-3’
  Rev 5’-TCA GCC ATT GAA CTC ACT T-3’
  Probe 5’-(FAM)-AGG TCA GAC TGG GCA GGA GAT-(TAMRA)-3’
upregulated upon GC exposure and whether the degree of upregulation was 
related to GC resistance, a linear mixed-effects model was fi tted to the log-2 
GR expressions, using as explanatory variables exposure time, GC sensitivity, 
prednisolone exposed or control sample, and the individual patient, the last 
one having a random effect, the others with fi xed effects. Log-2 transformed 
GR expression levels were used to correct for the non-normal distribution of the 
data. By associating a random effect to each patient in the study, the model not 
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Table 2. Patient characteristics.
  Base-line expression  Effect of GCs on 5’ 
  of 5’ GR promoter  GR promoter and 3’ 
  transcripts GR transcript levels
  N=48 N=22
Gender Male 28 12
 Female 20 10
Age 1-9 yr 36 11
 ≥ 10 yr 12 11
Immunophenotype Precursor B-ALL 36 9
 T-ALL 12 13
WBC < 50000 / μl 18 3
 ≥ 50000 / μl 30 19
In vitro prednisolone Sensitive 24 12
toxicity Resistant 24 10
only allows for samples corresponding to the same patient to be more correlated 
than otherwise, but also patients are taken as representing a larger population 
of similar patients. A p-value ≤ 0.05 was considered statistically signifi cant (two-
tailed tested). 
RESULTS
Base-line GR promoter usage. We explored whether GC resistant ALL cells utilize 
other promoter sites at the GR than GC sensitive cells. For this, expression levels 
from the fi ve different 5’ GR promoter transcripts, i.e. transcripts 1A1, 1A2, 1A3 
derived from promoter 1A, transcript 1B from promoter 1B and transcript 1C, from 
promoter 1C, were measured by quantitative real-time RT-PCR according to the 
strategy as outlined in Figure 1. This study included 24 ALL patients in vitro sensitive 
to prednisolone, who were matched each to an in vitro resistant patient (matching 
according to age, immunophenotype and WBC count). The patient characteristics 
are depicted in table 2. For each patient, GR 1A1, 1A2, 1A3, 1B and 1C transcript 
expression levels were calculated as percent of the total expression level of the 
fi ve transcripts combined. The highest expression was found for promoters 1B 
and 1C, i.e. median 15.9% and 80.8%, respectively. The GR transcripts derived 
from the 1A promoter were lower expressed at 0.02%, 0.08% and 2.8% for the 
1A1, 1A2 and 1A3 transcripts, respectively. In a matched pair analysis, we did not 
observe a relationship between the base-line expression levels of the fi ve different 
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Figure 2. 5’ GR promoter transcript expression for in vitro prednisolone sensitive 
and resistant children with ALL
The mRNA expression of the 5’ GR promoter transcript 1A1, 1A2, 1A3, 1B and 1C as 
percentage of total GR promoter expression for 48 patients is depicted. The results are 
depicted as median and P25 and P75 values. Comparisons in expression levels of these fi ve 
transcripts between GC sensitive and resistant patient samples was not signifi cant.
GR promoter transcripts and in vitro prednisolone toxicity (Figure 2), even when 
analyzing precursor B-ALL and T-ALL samples separately.
GC-induced GR promoter usage. We next investigated whether specifi c promoter 
transcripts of the GR gene were upregulated upon eight hours of prednisolone 
exposure. Patient characteristics are depicted in table 2. Similar to what was 
found for the base-line expression values, no signifi cant changes for the percent 
expression of the fi ve 5’ GR promoter transcripts (1A1-3, 1B and 1C) were found 
between in vitro prednisolone sensitive and resistant cases. (Figure 3)
GC-induced GR expression. The effect of GC exposure on GR mRNA expression 
levels was analyzed by incubating leukemic cells for 3, 8 and 24 hours in culture 
medium with or without prednisolone. Characteristics of the included patients 
are depicted in table 2. For each time point, mRNA expression levels of the 3’ 
GR splice variants GR-alpha, GR-beta and GR-P were determined relative to the 
reference genes GAPDH and RNaseP. Both reference genes revealed the same 
data and, therefore, in the remaining part of this paper we describe the results 
obtained with GAPDH only. Total GR mRNA expression levels were defi ned as the 
sum of GR-alpha, GR-beta and GR-P and are depicted in Figure 4. 
Using a linear mixed-effects model, we found the GR to be upregulated upon GC 
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Figure 3. Glucocorticoid sensitivity is not related to differential use of GR promoters 
after 8 hours prednisolone exposure in ALL
The ratio for the 5’ GR promoter transcripts between the prednisolone exposed and control 
samples was calculated. The results are depicted as median and P25 and P75 values.
Comparisons of the ratio’s of these fi ve transcripts between GC sensitive and resistant 
patient samples was not signifi cant.
Figure 4. Regulation of the glucocorticoid receptor upon prednisolone exposure in 
ALL
Leukemic cells were incubated in culture medium with or without 250 μg/ml prednisolone 
for three, eight and twenty-four hours. The total GR mRNA expression as sum of GR-alpha, 
GR-beta and GR-P, for both the prednisolone incubated and the control samples is depicted. 
The results are depicted as median and P25 and P75 values.
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exposure for 3, 8 and 24 hours as compared to the control samples, incubated 
without prednisolone (p=0.002). However, the degree of upregulation was not 
related to GC sensitivity (p=0.12). The relative distribution between GR-alpha, 
GR-beta and GR-P expression levels did not change over time (with median 
expression levels of 68.8%, 0.03% and 31.1%, respectively), in both the GC 
sensitive and resistant patient samples. 
No difference was found within T-ALL or precursor B-ALL samples when analyzed 
separately as well. In addition, the three 3’ GR transcripts (GR-alpha, GR-beta and 
GR-P) were also co-ordinately regulated in both sensitive and resistant patients. 
DISCUSSION
The ability to upregulate GR expression upon GC exposure may be related to GC 
sensitivity in ALL as suggested in the literature after several cell line studies.13, 
14 It is currently unknown whether GR upregulation upon GC exposure occurs 
in pediatric ALL cells directly obtained from patients and whether an inability to 
upregulate the GR is related to GC resistance. Also no studies have been performed 
to address whether differential expression of the fi ve different 5’ GR promoter 
transcripts (1A1, 1A2, 1A3, 1B and 1C) is linked to GC resistance. 
   Our study shows that the base-line relative expression of the fi ve different 5’ 
GR promoter transcripts in pediatric ALL samples was the same as described in 
cell lines19, 22: 1B (15.9%) and 1C (80.8%) are the most abundantly expressed, 
followed by 1A3 (2.8%), 1A2 (0.08%) and 1A1 (0.02%). No correlation between 
the base-line expression levels of the different 5’ GR promoter transcripts and GC 
sensitivity was found. This is in contrast with a recent study in which mouse T-
lymphocytes showing a relative high expression of the GR-1A promoter were more 
susceptible to GC induced cell death than those showing a relative low expression 
of GR-1A.28 Since these studies were done using T-lymphocytes only, we analyzed 
samples of patients with a precursor B-ALL and T-ALL separately. Again no relation 
between GR promoter expression and in vitro prednisolone toxicity was found. 
Since the GR-1A promoter contains a weak GRE sequence in contrast to the GR-
promoters 1B and 1C (in which no GRE can be recognized), the regulation of the 
three GR promoters upon GC exposure has been hypothesized to be different.21 
Differential regulation of the 5 different 5’ GR transcripts has been shown in two 
separate studies with the CEM-C7 T lymphoblast cell line as model system, in which 
GC treatment specifi cally led to the upregulation of 1A3 promoter transcripts.19, 22 
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However, in the present study we did not detect a signifi cant difference in the GC 
induced expression level of any of the fi ve different 5’ GR promoter transcripts, 
neither in the total study population, nor when analyzing the prednisolone sensitive 
versus resistant patient samples. Since all 5’ GR promoter transcripts (1A1-3, 1B 
and 1C) were activated at the same level, the GRE sequence such as present in 
promoter 1A but not 1B and 1C may not be functional in ALL cells. In vitro GC 
resistance was not caused by a differential regulation of the different GR promoter 
transcripts.
Besides promoter usage, the inability of leukemic cells to upregulate the GR 
upon GC exposure could be an explanation for GC resistance. In correspondence 
with leukemic cell line studies10-12, we also found an upregulation of the GR upon 
prednisolone exposure in leukemic blasts from children with ALL. In contrast, 
other human cell types, in which GCs do not induce apoptosis, are characterized 
by a downregulation of the GR upon GC exposure.6-8 Thus, upregulation of the GR 
may be an important hallmark of ALL cells that normally undergo apoptosis upon 
GC exposure. We found that the three 3’ GR splice variants GR-alpha, GR-beta 
and GR-P were co-ordinately regulated over time. The percentage of these three 
splice variants of total GR expression was the same as reported in the literature 
in non-GC-exposed ALL samples17 and did not change after 3, 8 and 24 hours 
prednisolone exposure. 
Since relatively large differences in the degree of regulation of the GR were 
observed between sensitive and resistant cell lines, it has been hypothesized that 
this difference underlies GC resistance in childhood ALL.13, 14 However, in our study 
we did not fi nd differences in the degree of regulation of GR mRNA between in vitro 
sensitive and resistant leukemic samples. Since the studies relating GC resistance 
to the level of GR upregulation have been done using T-cell leukemia cell lines, 
we also analyzed the precursor B-ALL and T-ALL samples separately. Again no 
relation between the level of GR regulation and GC resistance could be found. The 
3’ GR splice variants GR-alpha, GR-beta and GR-P were found to be co-ordinately 
regulated upon GC exposure in both sensitive and resistant ALL samples, ruling 
out the possibility that GC resistance is determined by a preferential regulation 
of GR-beta and GR-P that may inhibit GR-alpha function.15, 16 These results are in 
correspondence with one previous cell line study, in which GR-alpha and GR-beta 
mRNA expression levels were co-ordinately upregulated upon GC exposure.22
As an alternative explanation for GC resistance, it could be that instead of 
mRNA levels, protein levels of the GR upon GC exposure are correlated with 
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GC resistance (i.e. post-transcriptional regulation instead of transcriptional 
regulation). However, it has been demonstrated before in leukemic cell lines that 
the GC mediated upregulation of GR expression is a transcriptional response.10, 14, 
29 Unfortunately, we did not have suffi cient material to confi rm these cell line data 
in patient material. 
In conclusion, nor the base-line expression of the fi ve 5’ GR promoter transcripts, 
nor the expression of these after prednisolone exposition is related to GC resistance 
in pediatric ALL. Exposure to prednisolone did not induce a decrease of the GR 
as seen in other body tissues, but an upregulation in ALL cells. However, GC 
resistance in ALL is not related to a defective upregulation.
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ABSTRACT
Resistance to glucocorticoids (GC) is an important adverse risk factor in the 
treatment of acute lymphoblastic leukemia (ALL). To induce apoptosis, GCs bind 
to the GC receptor (GR), which is regulated by various (co)chaperone proteins like 
HSP-70, HSP-40, HIP, BAG-1, HOP, HSP-90, P-23, FKBP-51, FKBP-52 and CYP-
40. In this study, we tested the hypothesis that mRNA expression levels of these 
molecules are determinants of GC resistance in childhood ALL.
Methods. 20 children with ALL cells in vitro sensitive to prednisolone (LC50<0.1 
μg/ml) were compared each with a resistant patient (LC50>150 μg/ml), matched 
for immunophenotype, age and white blood cell count. mRNA expression levels 
of the (co)chaperone molecules were measured by quantitative real-time RT-PCR 
and normalized to GAPDH and RNaseP levels. In vitro resistance to prednisolone 
was measured by MTT assay.
Results. HSP-90 mRNA expression levels were 2000-fold higher as compared 
to HSP-70. Using matched pair analysis, mRNA expression levels of the various 
(co)chaperone molecules were not signifi cantly different between in vitro sensitive 
and resistant patients.
Conclusion. Glucocorticoid resistance in childhood ALL can not be attributed to 
different mRNA expression levels of the investigated (co)chaperone molecules, 
involved in GC binding and transport to the nucleus. 
INTRODUCTION
The glucocorticoids (GC) prednisone and dexamethasone have been used in the 
treatment of childhood acute lymphoblastic leukemia (ALL) since many decades. 
In vivo and in vitro response to GCs are strong prognostic factors for clinical 
outcome1-3, but mechanisms underlying GC resistance in childhood ALL remain 
largely unknown.4 After entering the cell by passive diffusion, GCs bind to 
the glucocorticoid receptor (GR). Binding depends on the assembly of various 
(co)chaperone proteins within a GR-chaperone complex, which directs the GR to 
adopt a GC-binding conformation. The fi rst step in this process is the binding of 
heat shock protein 70 (HSP-70) and HSP-40 to the GR in an energy-dependent 
process whereby BAG-1 (BCL-2 associated gene product-1) and HIP (HSP-70 
interacting protein) can act as negative and positive regulators respectively.5 
Secondly, HSP-90 and HOP (HSP-70 / HSP-90 organizing protein) bind to this 
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complex leading to opening of the GC-binding cleft of the GR in an ATP dependent 
way.5 This complex is stabilized by P-23 (protein 23) and several immunophillins 
like FKBP-51 (FK506 binding protein-51), FKBP-52 and CYP-40 (cyclophilin D).5, 6 
(Figure 1) Upon binding, the GC – GR complex is transported to the nucleus where 
it transactivates GC responsive genes and/or transrepresses other transcription 
factors like AP-1 and NF-κB. For the transport of the GC-GR complex into the 
nucleus, (co)chaperone molecules like HSP-90 and FKBP-52 are suggested to 
Figure 1. (Co)chaperone protein interactions with the glucocorticoid receptor 
(GR) 
The stepwise assembly of the glucocorticoid receptor – (co)chaperone complex, leading to 
opening of the GC binding cleft and enabling GC binding. In a fi rst, ATP dependent step, 
HSP-70 and HSP-40 bind to the GR. This step is inhibited by BAG-1 and activated by HIP. 
Hereafter HOP and HSP-90 bind to the GR, which opens, in an ATP dependent step, the 
glucocorticoid (GC) binding cleft, enabling the GR to bind GC. This complex is stabilized by P-
23 and the immunophilins FKBP-51, FKBP-52 and CYP-40. One of the models hypothesized 
in the literature is that FKBP-52 promotes binding of the GC-GR complex to Dyneins for 
transportation into the nucleus, whereas FKBP-51 promotes retainment of the complex in 
the cytoplasm.
be necessary for binding of the GC-GR complex to Dynein, which is part of the 
microtubule based movement machinery.5, 7 FKBP-51 has an opposite effect, 
keeping the complex in the cytoplasm.8
Sofar, only two (co)chaperone proteins have been studied in relation to GC 
resistance in ALL. Kojika et al. reported aberrant HSP-90 protein expression 
(80 and 160 kD instead of 90 and 180 kD) and extremely low HSP-70 protein 
expression in 2 out of 9 resistant human leukemic cell lines.9 In the only study 
using patient material, no relation was found between HSP-90 protein and mRNA 
expression, and in vivo GC sensitivity in children with ALL.10 
In the present study we tested whether GC resistance in childhood ALL is 
associated with altered mRNA expression of the GR (co)chaperone molecules HSP-
70, HSP-40, HIP, BAG-1, HOP, HSP-90, P-23, FKBP-51, FKBP-52 and CYP-40.
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MATERIAL AND METHODS
Patients. In this case control study, 20 patients in vitro sensitive to prednisolone 
(LC50<0.1 μg/ml) were matched each to a patient in vitro resistant to prednisolone 
(LC50>150 μg/ml). Patients were matched for age (1-10 years or ≥10 years), 
immunophenotype (common- / pre-B-ALL or T-ALL) and white blood cell count 
(WBC < 50000/μl or ≥50000/μl) at diagnosis. Patient material was taken at 
diagnosis with informed consent from the patients or their parents. 
The mononuclear cell fraction was separated by Lymphoprep density gradient 
centrifugation (density 1.077 g/m3, Nucomed Pharma, Oslo, Norway). When 
necessary, non-leukemic cells were depleted by immunomagnetic beads to purify 
the samples to more than 90% of blasts. 
   Isolation of RNA and cDNA synthesis. Total RNA was extracted using the Trizol 
method (Gibco BRL, Life Technologies, Breda, the Netherlands) according to the 
protocol provided by the manufacturer with minor modifi cations.11 RNA pellets 
were dissolved in 20 μl TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH= 8.0), and 
quantifi ed spectrophotometrically. cDNA was synthesized as described before11, 
diluted to a fi nal concentration of 8 ng/μl, and stored at -80°C. 
   Quantitative Real-time RT-PCR. mRNA levels of HSP-70, HSP-40, HIP, BAG-1, 
HOP, HSP-90, P-23, FKBP-51, FKBP-52, CYP-40 and GR-alpha (i.e. target PCRs) 
and two endogenous reference genes (i.e. GAPDH and RNaseP) were measured 
by quantitative real-time RT-PCR based on Taqman-chemistry using an ABI PRISM 
7700 sequence detector (Applied Biosystems, Foster City, CA, USA). PCR products 
were detected by a double labeled, non-extendible probe containing a FAM 
reporter group and a TAMRA quencher-group (table 1).11 All primers and probes 
had melting temperatures of 65±1oC and 75±1oC respectively (nearest neighbor 
method12). One hundred nanograms of genomic DNA served as a negative control 
and did not result in detectable amplifi cation for any of these reactions, confi rming 
the specifi city of these reactions for RNA detection. Forty nanograms of patient 
sample cDNA was amplifi ed in duplo in the presence of 300 nM forward and reverse 
primers, 50 nM probe, 200 μM dNTPs, 4 mM MgCl2 and 1.25 U of AmpliTaq
TM gold 
DNA polymerase in Taqman buffer A (Applied Biosystems) in a total volume of 
50 μl. Samples were heated for 10 min at 95°C and amplifi ed in 40 cycles of 15 
sec at 95°C and 60 sec at 60°C. A serial diluted positive control was amplifi ed 
on each plate to verify the amplifi cation effi ciency within each experiment.11 The 
average Ct-value was used to calculate the mRNA expression levels of the PCR 
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Table 1. Primer and probe combinations used for the quantitative real-time RT-
PCR. GenBank accession codes used for designing the primers and probes are depicted.
Gene Sequence
Hsp-90  Fw 5’ GAT AAA CCC TGA CCA TTC C 3’
NM005348 Rev 5’ TTT-ATG-AAA-CTG-CGC-TCC-TGT-CTT 3’
 Probe 5’ FAM - TTT-ATG-AAA-CTG-CGC-TCC-TGT-CTT - TAMRA 3’
Hsp-70 Fw 5’ GGA GGC GGA GAA GTA CA 3’
NM005345 Rev 5’ GCT GAT GAT GGG GTT ACA 3’
NM005346 Probe 5’ FAM - AGA TCA GCG AGG CGG ACA A - TAMRA 3’
Hsp-40  Fw 5’ CGC CGA GGA GAA GTT C 3’
NM006145 Rev 5’ CAT CAA TGT CCA TGC CTT 3’
 Probe 5’ FAM - TGA GTT CTT CGG TGG CAG AAA T - TAMRA 3’
P-23  Fw 5’ AAC GGA CAG ATC AAT TTT ATG 3’
NM006601 Rev 5’ TTG TGA ATC ATC ATC TGC TC 3’
 Probe 5’ FAM - TGA TGA ACA ACA TGG GTG GTG A - TAMRA 3’
HOP  Fw 5’ ATG ACC ACT CTC AGC GTC 3’
NM006819 Rev 5’ CTC CTT GGC TTT GTC GTA 3’
 Probe 5’ FAM - CAG TAT GGA TGA GCA GGA AGA GAT TG - TAMRA 3’
FKBP-51 Fw 5’ GAA TGG TGA GGA AAC GC 3’
NM004117 Rev 5’ ATG CCT CCA TCT TCA AAT AA 3’
 Probe 5’ FAM - TAT GGC TCG GCT GGC AGT C - TAMRA 3’
FKBP-52 Fw 5’ GCG GGG CAC TGT GTA 3’
NM002014 Rev 5’ AGC CAG CCT CTC AAA CA 3’
 Probe 5’ FAM - CAA CAA AGC CGA CAA GAC C - TAMRA 3’
CYP-40 Fw 5’ GCC-CTT-TTC-ATC-GAA-TTA-T 3’
NM005038 Rev 5’ ATA-TTC-CCC-CGT-CAT-CTC 3’
 Probe 5’ FAM - CAA GCA TGA TCG GGA GGG TT - TAMRA 3’
BAG-1 Fw 5’ GGG GTT CCA CAG TCT TTT 3’
NM004323 Rev 5’ CTG AAC CTT TTT TAC CAA GC 3’
 Probe 5’ FAM - AAT CTC TGA AGG AAA TGG AAA CAC C - TAMRA 3’
HIP  Fw 5’ CCG CAA AGT GAA CGA G 3’
NM003932 Rev 5’ TGA TGG TTC GTC TGC C 3’
 Probe 5’ FAM - CTG AGG GAG TGG GTG GAG AG - TAMRA 3’
GR-alpha Fw 5’ TGT TTT GCT CCT GAT CTG A 3’
AC012634 Rev 5’ TCG GGG AAT TCA ATA CTC A 3’
 Probe 5’ FAM - TGA CTC TAC CCT GCA TGT ACG AC - TAMRA 3’
GAPDH  Fw 5’ GTC GGA GTC AAC GGA TT 3’
ACJ04038 Rev 5’ AAGCTT CCC GTT CTC AG 3’
 Probe 5’ FAM - TCA ACT ACA TGG TTT ACA TGT TCC AA - TAMRA 3’
RNaseP  Fw 5’ TTG GGA AGG TCT GAG ACT A 3’
X15624 Rev 5’ TCA GCC ATT GAA CTC ACT T 3’
 Probe 5’ FAM - AGG TCA GAC TGG GCA GGA GAT - TAMRA 3’
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targets relative to the expression level of the two housekeeping genes using the 
comparative Ct method12 using the equation: 
relative expression = 2-[Ct(target)-Ct(reference gene)] x 100 .
   MTT-assay. In-vitro drug cytotoxicity was assessed using the MTT assay 
as described earlier.2, 13 Briefl y, patient blasts were cultured with or without 
prednisolone disodiumphosphate in a concentration range between 0.06 and 250 
μg/mL. At day 4, MTT is added which can only be reduced into formazan by 
viable cells. The reduced product was quantifi ed spectrophotometrically at 562 
nm. The leukemic cell survival was calculated by: (OD drug treated well / OD 
control wells without drug) x 100%. The LC50 value represents the concentration 
of the drug at which 50% of the cells are killed and is used as measure of in-vitro 
drug cytotoxicity. Leukemic cells having LC50 values lower than 0.1 μg/ml were 
assigned in vitro glucocorticoid sensitive, samples having LC50 values exceeding 
150 μg/ml were considered in vitro resistant, as previously described to be of 
prognostic value.13, 14
   Statistical methods. The non-parametric Wilcoxon signed rank test for matched 
samples and the non-parametric Mann-Whitney U test were used to analyze the 
results from the patient samples. A p-value ≤ 0.05 was considered statistically 
signifi cant (two-tailed tested). 
RESULTS
Forty patients were included in this case control study. For each in vitro sensitive 
patient, an in vitro resistant control, matched for age, immunophenotype and 
WBC, was selected. Patient characteristics are depicted in table 2. 
The expression levels of the different (co)chaperone molecules were measured 
by quantitative real-time RT-PCR. The PCR reactions were very specifi c, showing 
Table 2. Patient characteristics.
  N (%)
Gender Male 22 (55)
 Female  18 (45)
Age at diagnosis 1 – 9 yr 30 (75)
 ≥ 10 yr 10 (25)
WBC at diagnosis < 50000/ml 22 (55)
 ≥ 50000/ml 18 (45)
Immunophenotype Common- / pre-B-ALL 28 (70)
 T-ALL 12 (30)
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only one single PCR product of predicted size on gel. (Figure 2) Amplifi cation 
effi ciency was 95% or higher for all reactions (data not shown), which allows direct 
normalization of expression levels of each target PCR to the expression levels of 
the endogenous house-keeping genes GAPDH and RNaseP. Figure 3 shows the 
mRNA expression levels of the various (co)chaperone molecules relative to GAPDH 
for the whole study population. Compared to the other (co)chaperone molecules, 
the mRNA expression level of HSP-90 was relatively high, whereas the expression 
level of HSP-70 was relatively low, approximately 2000-fold lower than HSP-90. 
The median mRNA expression levels of the different (co)chaperone molecules and 
the GR for the in vitro sensitive and resistant patients are depicted in table 3. 
Figure 2. PCR products of the (co)chaperone molecules
Example of real-time RT-PCR products resolved on agarose gel for the various target genes 
as tested in this study, to show that the PCR reactions are very specifi c, resulting in only one 
PCR product per reaction.
Figure 3. Expression levels of (co)chaperone molecules in pediatric ALL cells
mRNA expression levels, relative to GAPDH, of all study patients are depicted. Lines indicate 
the median values.
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   Since we analyzed every GC sensitive patient in relation to its matched control, 
the ratios of the mRNA expression levels of the various (co)chaperone molecules 
for each prednisolone sensitive case relative to its matched prednisolone resistant 
control case were calculated and shown in Figure 4. The median ratio was about 
1 for each of the (co)chaperone molecules. Using a matched pair analysis, no 
Table 3. mRNA expression levels of the different (co)chaperone molecules and the 
glucocorticoid receptor relative to GAPDH for the in vitro sensitive and resistant 
patients.
 Sensitive patients Resistant patients
 Median (p25 – p75) Median (p25 – p75)
HSP-70 0.0001 (0.0001-0.0002) 0.0002 (0.0001-0.0008)
HSP-40 0.0045 (0.0027-0.0108) 0.0039 (0.0028-0.0100)
BAG-1 0.0055 (0.0038-0.0106) 0.0038 (0.0025-0.0083)
HIP 0.0156 (0.0101-0.0260) 0.0148 (0.0083-0.0203)
HOP 0.0033 (0.0018-0.0042) 0.0018 (0.0012-0.0024)
HSP-90 0.3148 (0.2232-0.4686) 0.2595 (0.1900-0.4662)
P-23 0.1156 (0.0751-0.1390) 0.0924 (0.0598-0.1217)
FKBP-51 0.0295 (0.0152-0.0537) 0.0170 (0.0100-0.0302)
FKBP-52 0.0044 (0.0010-0.0084) 0.0027 (0.0010-0.0094)
CYP-40 0.0029 (0.0020-0.0059) 0.0024 (0.0013-0.0049)
GR  0.0257 (0.0178-0.0326) 0.0158 (0.0092-0.0249)
Figure 4. Ratio of the (co)chaperone mRNA expression levels of the matched 
prednisolone sensitive and resistant ALL patients
Distribution of the ratio of the (co)chaperone molecules for the matched sensitive and 
resistant patients. mRNA expression levels, relative to GAPDH, were used for calculation of 
the ratio. Lines indicate the median values. 
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differences in expression for any of these molecules were found between in vitro 
sensitive and resistant patients. Normalization to RNaseP instead of GAPDH led to 
the same conclusions (data not shown).
   With BAG-1 being an inhibitor of HSP-70 and HIP being a positive regulator, 
the ratio of these 2 cochaperone molecules was determined and related to GC 
sensitivity. No difference was found between the matched in vitro sensitive and 
resistant patients with respect to the ratio of the mRNA expression levels of BAG-1 
and HIP. (Figure 5A) As FKBP-51 and FKBP-52 might compete for binding to the 
GR complex, thereby affecting the nuclear shuffl ing of the GC-GR complex, the 
ratio of these molecules was calculated and related to GC sensitivity. No difference 
for the FKBP-51 / FKBP-52 mRNA ratio was found between the matched in vitro 
prednisolone sensitive and resistant patients. (Figure 5B) Since HSP-90 has been 
reported to be involved in the stabilization of the GC-GR complex binding to the 
Figure 5. Ratio of the mRNA expression levels of various related (co)chaperone 
molecules
(a) The ratio of BAG-1 (a negative regulator of HSP-70) and HIP (a positive regulator of 
HSP-70). (b) The ratio of FKBP-51 and FKBP-52, which have been reported to compete with 
eachother for binding the GC-GR complex. Binding to FKBP-52 promotes shuttling to the 
nucleus and thereby promotes the anticipated effect of the GC. (c) The ratio of HSP-90 and 
P-23, reported to stabilize the binding of the GR to the promoter of GR responsive genes and 
to destabilize this binding respectively. (d) The ratio of HSP-90 and GR-alpha (the functional 
GR), which has been speculated to be related to GC sensitivity. Lines indicate the median 
values, NS means not signifi cant.
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promoter of GR responsive genes while P-23 has the opposite effect, the ratio 
of the mRNA expression levels of these molecules was studied in relation to GC 
resistance. However, we did not fi nd any difference between sensitive and resistant 
patients. (Figure 5C) The ratio of HSP-90 and the functional glucocorticoid receptor 
(GR-alpha) mRNA levels might be related to GC resistance as well. We were able 
to calculate a HSP-90 / GR-alpha ratio in 12 matched patient samples. No relation 
was found between this ratio and GC resistance. (Figure 5D)
DISCUSSION
GCs enter the cell by passive diffusion to bind the GR. To enable binding, the 
GR undergoes a stepwise maturation process in which it is bound by various 
(co)chaperone proteins, eventually leading to the opening of the GC binding 
pocket.5 (Figure 1) Which of the proteins are absolutely necessary for this process 
remains unclear. Some reports state that only HSP-90 and HSP-70 are minimally 
required15, but most studies report the necessity of at least 5 proteins (HSP-90, 
HSP-70, HSP-40, HOP and P-23).16, 17 
   In the present case control study we analyzed the mRNA expression levels of 
the (co)chaperone proteins of the GR in relation to GC resistance in childhood 
ALL. The chaperone molecule HSP-70 had a relatively low mRNA expression level, 
while the mRNA expression level of HSP-90 was relatively high (2000 fold higher 
than HSP-70 expression), which is in concordance with earlier studies reporting 
protein and mRNA levels of HSP-90 and HSP-70 in acute leukemias.10, 18, 19 As HSP-
70 is part of the more immature GR-(co)chaperone complex, its low expression 
level might determine a rate limiting step in the initial maturation process of the 
GR. For none of the (co)chaperone molecules as tested in this study, a relation 
between mRNA expression level and in vitro GC resistance was found. 
We tested different other hypotheses on a possible relation between GR 
(co)chaperone expression and GC resistance. The ratio of BAG-1, which is a 
negative regulator of HSP-7020 and HIP, which is a positive regulator might be 
correlated to GC resistance. 21 However, such a correlation was not found in our 
study population. BAG-1 is also reported to be an inhibitor of DNA binding and 
subsequent transcriptional activation by the GR22, but we did not fi nd a relation 
between BAG-1 mRNA expression levels and GC resistance either. 
   For transportation of the GC-GR (co)chaperone complex to the nucleus, FKBP-
51 is replaced by FKBP-52 in this complex. Some New World primate genera are 
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very resistant to GC. In these animals it was shown that an elevated protein 
expression of FKBP-51 contributed to GC resistance.23 Studies analyzing protein 
expression levels showed that FKBP-52 potentiates reporter gene activation, 
which is attenuated by FKBP-51.8, 24 We hypothesized that the ratio of FKBP-51 
and FKBP-52 mRNA levels is related to GC resistance. As we could not show such 
a correlation in our study population, and we did not show a relation between 
FKBP-51 mRNA expression and GC resistance either, the relevance of FKBP-51 for 
GC resistance as found in some new world primates can not be extrapolated to GC 
resistance in childhood ALL.
HSP-90 stabilizes the binding of the GC – GR complex to the promoter of GR 
responsive genes, while P-23 induces removal of this complex from the promoter.25 
Longer GR residence time at these promoter sites is associated with greater 
transcriptional output, so expression of HSP-90 and P-23 might be related to GC 
resistance. By studying the ratio of HSP-90 and P-23 mRNA expression levels and 
GC resistance, we conclude that this ratio is not correlated to GC resistance in 
childhood ALL. Another study reported a negative effect of HSP-90 protein levels 
on GR function when the ratio HSP-90/GR increased.26 No such negative effect of 
mRNA expression levels was found in our patient cohort.
The conclusion of an earlier study, that HSP-90 expression levels are not related to 
GC resistance10, are confi rmed in this (larger) study and we show that the mRNA 
expression levels of other (co)chaperone molecules of the GR are not related 
to GC resistance as well. It might be, that not mRNA levels, but protein levels 
of the different (co)chaperone molecules are correlated with GC resistance (i.e. 
post-transcriptional regulation instead of transcriptional regulation). However, a 
correlation between mRNA and protein levels has been shown previously for HSP-
90, HSP-70, BAG-1, FKBP-51 and FKBP-52 in different cell lines.27-31 Due to the 
limitation of patient material, it was not possible to confi rm these data in our 
population. Another hypothesis relating (co)chaperone molecules to GC resistance 
might be that not the expression level, but rather the functional capacity of the 
(co)chaperone molecules to form a complex with the GR instead of the expression 
level of the (co)chaperone molecules is related to GC resistance. This complex 
formation process might for example be infl uenced by mutations in one of the 
genes encoding for the (co)chaperone proteins. When one step of the maturation 
process of the GR is disturbed, GC binding might decrease, resulting in reduced 
transactivation or transrepression of GC responsive genes. Using dexamethasone 
binding assays, it was shown that decreased binding of dexamethasone was related 
Chapter 6
88
to GC resistance in childhood ALL. Although this fi nding was regarded to be due to 
a lower expression level of the GR32, it may alternatively be related to a reduced 
rate in complex maturation due to defects in one of these molecules other than 
just the expression level of these molecules. However, to study the formation of 
the GR – (co)chaperone complex will be very diffi cult when using patient material, 
as the different stages of this complex will pass quickly. A last hypothesis on the 
relevance of the (co)chaperone expression for GC sensitivity might be, that not 
the expression level before start of therapy, but the (co)chaperone expression 
level upon GC exposure is related to GC sensitivity and resistance. In this sense 
it is of interest that, using micro-array studies, one of the genes found to be 
upregulated upon GC exposure is FKBP-51.33 However, till date there are no data 
on differences in gene expression upon GC exposure between GC sensitive and 
resistant ALL cells. 
   In conclusion, childhood ALL cells have a relatively high mRNA expression level 
of HSP-90 and a low expression level of HSP-70. The expression levels of the 
different (co)chaperone molecules of the GR are not related to GC resistance. 
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ABSTRACT
Glucocorticoids are keystone drugs in the treatment of childhood acute 
lymphoblastic leukemia (ALL) and therefore it is important to get more insight in 
signal transduction pathways involved in glucocorticoid induced apoptosis in ALL. 
Affymetrix U133A GeneChips were used to identify genes that are transcriptionally 
regulated upon 3 and 8 hours of prednisolone exposure in leukemic cells of 13 
children newly diagnosed with ALL. Following 3 hours of exposure no signifi cant 
changes in gene expression could be identifi ed as compared to exposure to culture 
medium. Following 8 hours of exposure, 57 probesets (51 unique genes) were 
differentially expressed (p < 0.0005 and false discovery rate < 10%) with 44 
probesets (39 genes) being upregulated (median 2.4-fold) and 13 probesets 
(12 genes) downregulated (median 1.7-fold). Twenty-one of those genes have 
not been identifi ed before to be transcriptionally regulated by prednisolone. Two 
of the three most highly upregulated genes were tumor suppressor genes, i.e. 
Thioredoxin interacting protein (TXNIP, 3.7-fold) and Zinc fi nger and BTB domain 
containing 16 (ZBTB16, 8.8-fold). About 50% of the differentially expressed genes 
were functionally categorized in three major routes, namely MAPK pathways (9 
genes), NF-κB signaling (11 genes) and carbohydrate metabolism (5 genes). 
Biological characterization of these genes and pathways might elucidate the 
action of glucocorticoids in ALL cells, which may point to causes of glucocorticoid 
resistance, ways to circumvent glucocorticoid resistance and new potential targets 
for therapy. 
INTRODUCTION
Glucocorticoids like prednisone and dexamethasone have been used extensively in 
the treatment of childhood acute lymphoblastic leukemia (ALL) since many years. 
The in vivo and in vitro prednisone response as determined with a tetrazolium-
based (MTT) toxicity assay have been shown to correlate with each other and 
long-term clinical outcome in children with ALL.1-3 
   The classically proposed way of glucocorticoid action is that glucocorticoids bind 
to the intracellular glucocorticoid receptor (GR). The glucocorticoid-GR complex 
then translocates to the nucleus, where it binds to glucocorticoid responsive 
elements (GRE), resulting in the transcriptional activation of glucocorticoid-
responsive genes.4 Alternatively, the glucocorticoid-GR complex can directly bind 
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to transcription factors like Nuclear Factor-κB (NF-κB) or Activator Protein-1 (AP-
1), resulting in so-called transrepression complexes. These complexes disrupt the 
transcriptional regulation of genes that are normally affected by these transcription 
factors.5 Depending on the cell type, transcriptional activation and repression 
result in immunosuppression, stress response or induction of apoptosis. 
Interestingly, glucocorticoids only induce apoptosis in lymphoid cells like 
ALL, multiple myelomas, malignant lymphomas and thymocytes, not in other 
tissues. Nevertheless, despite the major impact of glucocorticoid resistance on 
clinical outcome, knowledge about the signal transduction pathways leading to 
glucocorticoid induced apoptosis in ALL cells is limited.6, 7 Several microarray studies 
have been performed to determine glucocorticoid-regulated genes in leukemia. 8-
12 However, the cell lines (i.e. immortalized cells) as used in these studies do not 
represent an ideal model to study mechanisms involved in survival and apoptosis 
of primary ALL cells. Recently the fi rst microarray study was published in which, 
besides cell lines, in vivo prednisone-exposed patient ALL samples were analysed.13 
In the present study, we used freshly obtained leukemic cells of pediatric patients 
at initial diagnosis of ALL to identify which genes are transcriptionally regulated 
upon in vitro prednisolone exposure.
MATERIAL AND METHODS
Patients. The study population consisted of 13 patients diagnosed with 
precursor-B or T-ALL. Pretreatment bone marrow or peripheral blood was obtained 
after written informed consent from the patients and/or their legal guardians. 
The mononuclear cell fraction was separated by Lymphoprep density gradient 
centrifugation (density 1.077 g/ml, Nycomed Pharma, Oslo, Norway). When 
necessary, non-leukemic cells were depleted by immunomagnetic beads to purify 
the samples to more than 90% of leukemic cells. 
   Prednisolone exposure. Leukemic cells were incubated in RPMI 1640 medium 
(Dutch modifi cation without L-glutamine) supplemented with 2 mM L-glutamine, 5 
µg/ml insulin, 5µg/ml transferrin, 5 ng/ml sodium selenite, 20% heat-inactivated 
fetal calf serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, 0.125 µg/ml 
fungizone, 200 µg/ml gentamycin with and without 250 μg/ml prednisolone. After 
3 and 8 hours of incubation, 20 x 106 cells were removed from the culture for RNA 
isolation. 
   RNA extraction, labeling and hybridization. Total RNA was extracted using the 
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Trizol method (Gibco BRL, Life Technologies, Breda, the Netherlands) according to 
the protocol provided by the manufacturer with minor modifi cations.14 RNA integrity 
was determined using the Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). 
RNA (5-15 μg) was used for subsequent production of biotinylated antisense cRNA, 
as described before.15 Samples with less than 10 μg labeled cRNA were excluded. 
Labeled cRNA was hybridized to the U133A GeneChip oligonucleotide microarray 
(Affymetrix) according to the protocol provided by the manufacturer.
Statistics. Raw gene expression values were calculated using Affymetrix 
Microarray Suite version 5.0.16 Data were normalized using the variance stabilization 
procedure (VSN) as proposed by Huber et al.17 Data distribution of unexposed 
controls suggested a gamma- or log-normal distribution. Therefore a generalized 
linear model with gamma error distribution and identity link function was used 
to describe the effect of exposure (prednisolone exposed or control) on gene 
expression levels. This model was fi tted to each gene separately and the effect 
of exposure was evaluated via the corresponding ANOVA p-values. Differentially 
expressed genes with respect to exposure were selected by controlling the false 
discovery rate (FDR), using Benjamini & Hochberg’s procedure.18 A p-value < 
0.0005 and a FDR (adapted for multiple testing) < 10% was considered statistically 
signifi cant. Normalization and subsequent analysis were run using R 1.9.119, also 
making use of the Bioconductor packages VSN and Multtest. (www.Bioconductor.
org, see URL) The fold up- or down-regulation was calculated using the formula: 
e (vsn value pred sample – vsn value control sample).
The TELiS database (www.telis.ucla.edu/index.htm)20 was used to search for 
transcription factor binding motifs (TFBMs) which were over- or underrepresented 
in the genes differentially expressed upon prednisolone exposure, using a promoter 
size of –1000 to + 200 and a stringency of 0.9.
RESULTS
Diagnostic samples of thirteen patients with ALL were exposed to prednisolone for 
three and eight hours. Prednisolone exposed and control (culture medium only) 
leukemic cells of the same patient were analyzed pairwise per patient to correct 
for the effect of culture in time. Paired samples could be successfully analyzed for 
9/13 patients at three hours and for 10/13 patients at eight hours of exposure 
time.
After 3 hours of prednisolone exposure, no differentially expressed probesets 
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Table 1. Prednisolone induced changes in gene expression in pediatric ALL. 
After 8 hours of prednisolone exposure, 57 probesets (51 unique genes and 2 ESTs) were 
differentially expressed at p<0.0005 and FDR<10%. Aliases between brackets.
probe ID Accession No Gene Name# Description Fold  p-value
    change* 
          Upregulated genes
204560_at NM_004117 FKBP5 FK506-binding protein 5 35.4 2.7e-07
205883_at NM_006006 ZBTB16 (PLZF) zinc fi nger and BTB domain containing 16 8.8 6.0e-05
201008_s_at AI439556 TXNIP (VDUP) thioredoxin interacting protein 4.4 8.7e-06
201009_s_at AA812232 TXNIP (VDUP) thioredoxin interacting protein  3.0 0.0002
221756_at AL540260 LIMK2 LIM domain kinase 2  4.1 6.8e-06
212158_at AL577322 SDC2 syndecan 2  4.0 1.6e-05
204698_at U88964 ISG20 interferon stimulated exonuclease gene 20kDa  3.7 3.3e-05
33304_at NM_002201 ISG20 interferon stimulated exonuclease gene 20kDa 3.4 1.2e-05
201369_s_at U07802 ZFP36L2 (ERF2) zinc fi nger protein 36, C3H type-like 2  3.6 6.1e-06
201368_at NM_006887 ZFP36L2 (ERF2) zinc fi nger protein 36, C3H type-like 2 2.6 2.2e-07
208078_s_at NM_030751 /  TCF8 / SNF1LK transcription factor 8 (represses interleukin 2 expression) 3.5 6.3e-05
 NP_775490   / SNF1-like kinase  
208763_s_at AL110191 DSIPI (TSC22D3,  delta sleep inducing peptide, immunoreactor 3.3 5.5e-05
  GILZ)    
202670_at AI571419 MAP2K1 (MEK1) mitogen-activated protein kinase kinase 1  3.1 1.1e-05
203542_s_at NM_001206 KLF9 (BTEB1) kruppel-like factor 9  3.1 0.0002
203543_s_at AI690205 KLF9 (BTEB1) kruppel-like factor 9  3.1 5.5e-05
203574_at NM_005384 NFIL3 nuclear factor, interleukin 3 regulated  3.0 7.5e-06
209185_s_at AF073310 IRS2 insulin receptor substrate 2 2.8 7.7e-06
215890_at X61094 GM2A GM2 ganglioside activator  2.6 2.0e-05
203973_s_at NM_005195 CEBPD CCAAT/enhancer binding protein (C/EBP), delta  2.5 3.4e-05
213792_s_at AA485908 INSR insulin receptor  2.5 0.0001
212242_at AL565074 TUBA1 tubulin, alpha 1 (testis specifi c)  2.4 0.0001
201041_s_at NM_004417 DUSP1 (MKP1) dual specifi city phosphatase 1  2.4 5.9e-05
212188_at AI718937 KCTD12 potassium channel tetramerisation domain containing 12  2.3 4.9e-06
212192_at AA551075 KCTD12 potassium channel tetramerisation domain containing 12 2.3 3.5e-05
218638_s_at NM_012445 SPON2 spondin 2 2.3 4.6e-05
207996_s_at NM_004338 C18orf1 chromosome 18 open reading frame 1  2.2 9.6e-06
204618_s_at NM_005254 GABPB2 GA binding protein transcription factor, beta subunit 2 2.2 4.3e-05
210001_s_at AB005043 SOCS1 suppressor of cytokine signaling 1  2.2 0.0002
200921_s_at NM_001731 BTG1 B-cell translocation gene 1, anti-proliferative  2.2 6.1e-05
202643_s_at AI738896 TNFAIP3 (A20) tumor necrosis factor, alpha-induced protein 3  2.1 0.0001
201037_at NM_002627 PFKP phosphofructokinase, platelet  2.0 0.0002
207945_s_at NM_001893 CSNK1D casein kinase 1, delta  1.8 6.1e-05
201739_at NM_005627 SGK serum/glucocorticoid regulated kinase  1.8 0.0002
203819_s_at AU160004 IMP-3 IGF-II mRNA-binding protein 3 1.7 2.1e-05
221563_at N36770 DUSP10 (MKP5) dual specifi city phosphatase 10  1.5 6.9e-05
215977_x_at X68285 GK glycerol kinase  1.5 6.4e-05
213310_at AI613483 EIF2C2 eukaryotic translation initiation factor 2C, 2  1.4 0.0001
215046_at AL133053 FLJ23861 EST 1.4 0.0002
217356_s_at S81916 PGK1 phosphoglycerate kinase 1  1.4 0.0001
211926_s_at AI827941 MYH9 myosin, heavy polypeptide 9, non-muscle  1.3 2.3e-05
218761_at NM_017610 RNF111 (ARK) ring fi nger protein 111 1.3 6.8e-05
217795_s_at W74580 THEM43 transmembrane protein 43  1.3 8.1e-05
201859_at NM_002727 PRG1 proteoglycan 1 1.3 0.0001
218528_s_at NM_022781 RNF38 ring fi nger protein 38  1.3 0.0001
         Down regulated genes
205749_at NM_000499 CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1  - 2.0 8.6e-06
209969_s_at BC002704 STAT1 signal transducer and activator of transcription 1 - 2.0 0.0001
219066_at NM_021823 MDS018 EST - 2.0 0.0001
205013_s_at NM_000675 ADORA2A adenosine A2a receptor  - 2.0 0.0001
205006_s_at NM_004808 NMT2 N-myristoyltransferase 2  - 1.7 6.4e-05
203612_at NM_004053 BYSL bystin-like  - 1.7 0.0002
219665_at NM_024815 NUDT18 nudix-type motif 18  - 1.7 3.5e-05
221933_at AI338338 NLGN4X neuroligin 4, X-linked  - 1.7 9.8e-05
204070_at NM_004585 RARRES3 retinoic acid receptor responder (tazarotene induced) 3 - 1.7 0.0002
211430_s_at M87789 IGHG1 immunoglobulin heavy constant gamma 1  - 1.4 7.7e-05
218046_s_at NM_016065 MRPS16 mitochondrial ribosomal protein S16  - 1.4 8.9e-06
219344_at NM_018344 SLC29A3 (ENT3) solute carrier family 29, member 3  - 1.4 2.7e-05
203814_s_at NM_000904 NQO2 NAD(P)H dehydrogenase, quinone 2  - 1.4 4.8e-05
# Human genome nomenclature
* The fold change refl ects the change in expression of genes after 8 hours prednisolone exposure compared to culture medium exposed control 
cells
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were identifi ed at the p < 0.0005 and FDR < 10% level. However, 2 genes were 
differentially expressed with p < 0.005 and FDR < 20%, i.e. ZFP36L2 (zinc fi nger 
protein 36, C3H type-like 2) and DSIPI (delta sleep inducing peptide, immunoreactor, 
alias GILZ). Eight hours of prednisolone exposure revealed differential expression 
of 57 probesets (51 unique genes and 2 expressed sequence tags -ESTs) at p 
< 0.0005 and FDR < 10% level. As shown in Table 1, 44 probesets (39 genes) 
were upregulated (median 2.4-fold, 25th-75th percentile: 1.8 - 3.1 fold) and 13 
probesets (12 genes) were downregulated (median 1.7-fold, 25th-75th percentile: 
1.5 – 2 fold). Probeset 208078_s_at represented 2 different genes: TCF8 and 
SNF1LK. Analysis at lower signifi cance level (p < 0.001 and FDR < 20%) revealed 
that 144 probesets were differentially expressed. 
As shown in Figure 1A the top 10 probesets that were found to be signifi cantly 
upregulated at p < 0.005 and FDR < 10% level after eight hours of prednisolone 
Figure 1. Comparison between three and eight hours on prednisolone-induced 
changes in gene expression in pediatric ALL
The fold up- (A) and down- (B) regulation of the top 10 probesets that were affected after 8 
hours of prednisolone exposure are shown at both three (white bars) and eight (black bars) 
hours of exposure. The median fold change is given.
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Table 2. Genes differentially expressed upon 8 hours prednisolone exposure in 
this study and previously reported in the literature.
gene Child ALL Lymphoid cell Cell line studied* reference
 (this study) lines (literature)
 Up- or down Up- or down
 Regulation regulation
ZFP36L2 Up Up 697 11
FKBP5 Up Up 697,Jurkat, CEM 9-11
LIMK2 Up Up CEM 38, 43
NFIL3 Up Up CEM 38, 43
ISG20 Up Up 697 11
TXNIP Up Up 697, CEM 8, 10, 38, 43
C18ORF1 Up Up CEM 8, 43
BTEB1 Up Up 697 10
DUSP1 (MKP-1) Up Down#  697 10
DSIPI (GILZ) Up Up 697, CEM 8, 10
BTG1 Up Up WEHI7.2, S49.A2, CEM, 697 11, 12, 38, 43
ZBTB16 Up Up CEM 8
TCF8 / SNF1LK Up Up 697 11
TUBA1 Up Up CEM 38, 43
DUSP10 (MKP-5) Up Down 697 10
PGK1 Up Down CEM 8
SGK Up Up WEHI7.2, S49.A2 12
PRG1 Up Up CEM, 697 10, 38, 43
EIF2C2 Up Down CEM 38, 43
PFKP Up Down WEHI7.2, S49.A2 12
BYSL Down Down CEM 8, 43
SOCS1 Up Up CEM, 697 8, 11, 38, 43
 Child ALL  Non-Leukemic cell
 (this study) lines (literature)
 Up- or down Up- or down
 Regulation regulation 
  
MAP2K1 Up Up Human bone marrow stromal cells  44
   (TM5)
SDC2 Up Up Human glomerular epithelial cells 45
CEBPD Up Up Different rat and rabbit cell types 46
GK Up Up Rat adipocytes 47
STAT1 Down Down Human peripheral blood mononuclear 48
   cells
INSR Up Up Human promonocytic cells 49
CYP1A1 Down Up Human aorta endothelial cells 50
*697: Human pre-B leukemia cell line
Jurkat: T-lineage leukemic cell line
CEM: T-lineage leukemic cell line
WEH17.2: T-cell lymphoma cell line
S49A2: T-cell lymphoma cell line
# upregulation reported in non-leukemic cell lines51
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Table 3. Biological function of prednisolone responsive genes in pediatric ALL.
The function of the different genes was studied in the literature (PUBMED search). Some 
genes have multiple functions, depending on cell type, stage in cell cycle.
Pro-apoptotic Proliferation Metabolism Other unknown
                ADORA2A CYP1A1 (drug  FKBP5 KCTD12
  metabolizing enzyme)
                   NFIL3  GM2A (glycosphingolipid LIMK2 C18orf1
   metabolism)
                  ZBTB16 IRS2  MYH9 SDC2
STAT1  GK SLC29A3 RNF38
ISG20 ZFP36L2  INSR        (carbohydrate  CEBPD BYSL
                  metabolism)
TXNIP MAP2K1  PGK1 KLF9 THEM43
BTG1 CEBPD PFKP NQO2 NUDT18
RARRES3 DUSP1 (MKP-1) SGK SPON2 
SOCS1 NMT2  CSNK1D 
DSIPI (GILZ) RNF111   TCF8 / SNF1LK 
 
 DUSP10 (MKP-5)  IGHG1 
 TNFAIP3  TUBA1 
 SGK  NLGN4X 
 IMP-3  PRG1 
   EIF2C2 
   GABPB2 
   MRPS16 
Bold letters indicate genes that are downregulated upon glucocorticoid exposure
exposure were also upregulated after three hours of prednisolone exposure albeit 
at a lower signifi cance (p-value < 0.05). Seven of the ten most signifi cantly 
downregulated genes at eight hours of prednisolone exposure were also 
downregulated after three hours of prednisolone exposure but a much lower 
signifi cance (p < 0.35) (Figure 1B).
Table 2 shows a summary of literature on previously identifi ed prednisolone-
responsive genes in leukemic cell lines (23 genes) and non-leukemic cells 
(7 genes) that were also found in the present study to be affected after eight 
hours of prednisolone exposure in primary ALL cells. Five genes were found to 
be upregulated in our study but downregulated in array studies that included 
leukemic cell lines: DUSP1(although reported to be upregulated in mast cells and 
fi broblasts), DUSP10, PGK1, EIF2C2 and PFKP. CYP1A1 was found to be the most 
prominently downregulated gene in primary ALL cells. In contrast, this gene was 
found to be upregulated in human aorta endothelial cells.
Forty out of the 51 genes (57 probesets) differentially expressed upon 
prednisolone exposure had an annotation in the Gene Ontology database. The 
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Table 4. Transcription factor binding motifs in prednisolone responsive genes.
Transcription factor binding motifs (TFBMs) over- / under-represented in 39 genes upregu-
lated upon 8 hours prednisolone exposure.
Transcription factor TBFM matrix Fold difference* p-value
Over-represented   
cAMP responsive element binding protein V$CREB_Q2 2.8 0.0002
CRE-binding protein 1 V$CREBP1_Q2 2.8 0.0061
cAMP responsive element binding protein V$CREB_02 2.5 7.8e-05
activator protein 2 V$AP2_Q6 2.5 6.9e-07
cAMP responsive element binding protein V$CREB_01 2.5 0.0028
cAMP responsive element binding protein V$CREB_Q4 2.2 0.0063
stimulating protein 1 V$SP1_Q6 2.1 5.5e-05
GC box elements V$GC_01 1.9 0.0024
F1 V$MZF1_01 1.6 6.4e-05
stimulating protein 1 V$SP1_01 1.6 0.0037
activator protein 4 V$AP4_Q5 1.4 0.0055
Under-represented   
YY1 - yin and yang 1 V$YY1_01 - 2.5 0.0006
octamer factor 1 V$OCT1_03 - 2.0 0.0018
GATA binding factor 3 V$GATA3_01 - 1.4 0.0074
GATA binding factor 1 V$GATA1_01 - 1.3 0.0024
GATA binding factor 2 V$GATA2_01 - 1.3 0.0041
cap signal for transcription initiation V$CAP_01 - 1.1 0.0009
* Fold difference in the frequency of specifi ed TFBMs in upregulated genes compared to 
the frequency observed in genes that are not differentially expressed upon prednisolone 
exposure.
representation of these 40 probesets in each of the functional categories did not 
statistically differ from the total of U133A Gene Chip probesets that are annotated 
by Gene Ontology. Besides analysis through the Gene Ontology database, we also 
analyzed the literature for putative functions of the 51 genes. (Table 3) Among 
the 51 prednisolone responsive genes, two of the three most highly upregulated 
genes are the putative tumor suppressor genes TXNIP (Thioredoxin interacting 
protein, alias VDUP1, 3.7 fold) and ZBTB1 (Zinc fi nger and BTB domain containing 
16, alias PLZF, 8.8 fold). Besides these two cell-cycle involved tumor suppressor 
genes, ~50% of the prednisolone-responsive genes could be assigned to three 
major pathways, i.e. the MAPK pathways (9 genes), NF-κB signaling pathways of 
gene transcription (11 genes), and carbohydrate metabolism (5 genes). 
Coordinated up- and downregulation of multiple genes upon prednisolone 
exposure may depend on the presence of specifi c transcription factor binding 
motifs (TFBMs) in the promoter regions of genes. Forty-fi ve of the 51 genes were 
annotated in the TELiS database, of which 35 genes were upregulated and 10 
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genes were downregulated upon prednisolone exposure. Seventeen TFBMs were 
found to be over- or underrepresented in the upregulated genes compared to 
non-regulated genes (p-value < 0.01 and a FDR < 14%). Of these 17 TFBMs, 11 
were over-represented and 6 were under-represented. (Table 4) cAMP responsive 
element binding protein (CREB) is the most often represented TFBM in the 
upregulated genes. The number of 12 downregulated genes was too small to allow 
for a meaningful analysis. 
   Although this study contained both in vitro prednisolone sensitive and resistant 
cases, the sample size in each subgroup was too small for a statistically relevant 
analysis. 
DISCUSSION
Despite the clinical importance of glucocorticoids in the treatment of ALL, the 
genes which are transcriptionally regulated upon glucocorticoid exposure in 
pediatric ALL and the specifi c (in)activation of pathways leading to glucocorticoid 
induced apoptosis are unknown. 
   In the present study, 3 hours of prednisolone exposure did not suffi ciently alter 
the level of gene expression to be able to (statistically) discriminate prednisolone 
responsive genes in pediatric ALL. In contrast to these primary cells, in leukemic 
cell lines signifi cant changes in gene expression can be observed already after 
3 hours of prednisolone exposure.8, 9 The same phenomenon that leukemic cell 
lines respond faster to a drug than corresponding primary cells was found for L-
asparaginase.21 Besides the faster response, also different genes were found to 
be affected by these drugs in the leukemic cell lines. These studies emphasize 
the fact that leukemic cell lines behave differently to drugs than primary cells and 
hence may not be suitable models for pharmacodynamic studies. 
Exposure of pediatric ALL cells for eight hours to prednisolone affected the 
expression of 57 probesets (51 genes); 44 probesets were upregulated and 13 
probesets were downregulated. FKBP5 (FK506 binding protein 5) was the most 
signifi cantly upregulated gene (35-fold). Its product, FKBP-51, functions as co-
chaperone molecule of the glucocorticoid receptor that affects the transport of 
the glucocorticoid receptor into the nucleus. The expression of this gene has been 
reported before to be highly glucocorticoid-inducable in cell lines and primary 
patient’s cells.13, 22, 23 The most signifi cantly downregulated gene was CYP1A1 (2-
fold) which is involved in drug metabolism and detoxifi cation. Although we found 
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only 57 probesets signifi cantly regulated upon 8 hours prednisolone exposition, 
more prednisolone-responsive genes can be identifi ed if less stringent cut-off 
levels are used for the p-value and FDR. For example, at p < 0.001 and FDR < 
20% 144 probesets are regulated upon 8 hours prednisolone exposure.
   Interestingly, a gene expression profi ling study has been published recently in 
which glucocorticoid-responsive genes were studied in both leukemic cell lines and 
primary cells of pediatric ALL.13 In that study other statistical considerations were 
made than in our study, such as a minimal change in gene expression of 1.6-fold 
in at least 6 our of 13 studied patients. Despite differences in methodology, fi ve 
out of 28 identifi ed responsive genes found in patients that were in vivo treated 
with prednisone (FKBP5, SOCS1, ZFP36L2, SNF1LK and ZBTB16) were also found 
in our study using in vitro exposed leukemic cells of children with ALL.
Signal transduction pathways possibly involved in glucocorticoid induced 
apoptosis
   TXNIP / ZBTB16. Both TXNIP and ZBTB16 were found to be upregulated following 
8 hours of prednisolone exposure in the present study. TXNIP has recently been 
described as a tumor suppressor protein that induces a cell cycle arrest upon 
formation of a transcriptional repressor complex with ZBTB16.24 TXNIP prevents 
thioredoxin-mediated apoptosis signal-regulating kinase 1 (ASK1) ubiquitination 
and degradation25, 26, and inhibits the thioredoxin radical scavenging function.27 
Thereby, TXNIP can act as a pro-apoptotic regulator. These data support a role for 
these genes in the induction of apoptosis upon prednisolone exposure in childhood 
ALL, as has been suggested recently by Wang et al..28
   
MAP kinase pathways. In the group of 51 prednisolone-regulated genes, 9 genes 
were associated with the three mitogen-activated protein (MAP) kinase pathways, 
i.e. ERK, JNK and p38 MAPK. These MAP kinase pathways are involved in cell 
survival (ERK and JNK) and cell death (p38 MAPK) and have been reported to 
play critical roles in the pathogenesis of various hematological malignancies.29, 
30 Miller et al. recently showed that pharmacological inhibition of ERK and JNK 
enhanced glucocorticoid-induced apoptosis, whereas inhibition of p38 MAPK 
activity opposed glucocorticoid-induced apoptosis in lymphoid cells.31 Four genes 
(DUSP1, DUSP10, DSIPI (alias GILZ) and SGK) that we found to be induced upon 
prednisolone exposure are negative regulators of the MAP kinase pathways. 
In the literature, overexpression of DSIPI was shown to promote apoptosis in 
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thymocytes.32 Overexpression of DUSP1 in a precursor-B ALL cell line did not 
alter glucocorticoid sensitivity33, suggesting that DUSP1 may not be essential for 
mediating the toxic effect of glucocorticoid in ALL cells. SGK is related to the PI3K 
/ AKT pathway (which is linked to the ERK pathway) and has been reported to be 
a survival molecule.34
Since we found both positive and negative regulators of the MAPK pathways among 
the prednisolone regulated genes, the net effect of these genes on cell survival 
needs to be addressed in functional studies in childhood ALL.
NF-κB. There are two classically proposed ways of an inhibitory effect of 
glucocorticoids on NF-κB function. First, the glucocorticoid-GR complex may 
interact with NF-κB directly, thereby opposing its function. Secondly, glucocorticoids 
upregulate IκBα (inhibitor of NF-κB α), which negatively regulates NF-κB. However, 
we did not fi nd a signifi cant upregulation of IκBα in our study (p = 0.002, FDR 
30%). Other postulated mechanisms of glucocorticoid mediated inhibition of NF-κB 
are the glucocorticoid induced upregulation of DSIPI and TNFAIP3.35, 36 Both genes 
were identifi ed in our study as prednisolone-responsive genes (3.35 fold and 2.12 
fold respectively, p < 0.0005 and FDR < 10%). This observation implies that the 
last two mechanisms might be more relevant for NF-κB inhibition (and hence 
induction of apoptosis) than the two classically proposed models in childhood 
ALL.
Carbohydrate metabolism. Five genes directly involved in carbohydrate 
metabolism are upregulated upon prednisolone exposure: IRS2, INSR, PFKP, GK 
and PGK1. Activity of these 5 genes results in higher ATP levels in the cell due to a 
higher glucose uptake of the cell (IRS2 and INSR), a higher rate of glyconeogenesis 
(GK) and glycolysis (PFKP and PGK1). Interestingly, in an earlier study looking 
for the baseline expression of genes determining glucocorticoid resistance in 
primary, untreated ALL cells, we found GLUT3 and GAPDH, two genes involved 
in carbohydrate metabolism to be overexpressed in prednisolone resistant ALL 
cells.16 Moreover, the glycolytic rate of prednisolone resistant leukemic cell lines 
was higher as compared to sensitive cell lines and inhibition of glycolysis by 2-
deoxy-D-glucose sensitized resistant cells to prednisolone whereas no effect on 
sensitive cells was found. (Holleman, manuscript in preparation) Taken together, 
these studies strongly suggest an important role for carbohydrate metabolism in 
glucocorticoid induced apoptosis. 
Transcription factor binding motifs. The TELiS database20 was used to study which 
TFBMs were over- or under-represented in the 39 upregulated genes. (Table 4) 
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Four TFBMs representing cAMP responsive element binding protein (CREB) were 
overrepresented in the promoter regions of the 35 upregulated genes as compared 
to non-regulated genes. CREB is a ubiquitous transcription factor involved in cell 
proliferation and survival. Interestingly, the interaction between glucocorticoids 
and CREB has been reported before.37 Forskolin was shown to increase cellular 
cAMP levels and to promote the phosphorylation of CREB. In combination with 
dexamethasone, forskolin synergistically induced apoptosis in the glucocorticoid 
resistant CEM-C1 lymphoid cell line, suggesting a role for CREB in glucocorticoid 
response. Surprisingly, the glucocorticoid responsive element (GRE) sequence 
was not over-represented in the promoter regions of the 35 upregulated genes, 
which is in line with a previous report on glucocorticoid induced genes in three ALL 
cell lines.38 However, at least three out of the 51 genes found to be regulated upon 
prednisolone exposure, contain GREs in the promoter regions, namely FKBP523, 39, 
DSIPI40 and SGK.41, 42 The fact that the GRE TFBMs were not overexpressed in the 
upregulated genes in our study, might be the result of the delicate positioning of 
GRE-like sequences in glucocorticoid responding genes, that are not recognized 
in the TELiS database. Another explanation might be that some genes are 
regulated “directly” by glucocorticoids binding to their GREs, whereas other genes 
are regulated more “indirectly” by other transcription factors, which in turn are 
regulated by glucocorticoids. 
   In conclusion, we found 51 prednisolone responsive genes in leukemic cells 
taken from children at initial diagnosis of ALL. Further functional research may 
identify which genes/pathways are essential for the glucocorticoid-responsiveness 
of cells. Out of the 51 identifi ed glucocorticoid-responsive genes, 50% can be 
linked to 3 pathways, i.e. cell proliferation and survival, NF-κB signalling and 
glucose metabolism. Two of the upregulated genes are tumorsuppressor genes: 
TXNIP and ZBTB16, which is possibly related to the induction of apoptosis by 
glucocorticoids. Knowledge on the pathways leading to glucocorticoid induced 
apoptosis is essential to develop more targeted therapy and ways to modulate 
glucocorticoid resistance in pediatric ALL
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SUMMARY
Children who are diagnosed with acute lymphoblastic leukemia (ALL) have 
a relatively good prognosis: the event-free survival in most current treatment 
protocols is about 75-80%. Both an in vivo and in vitro poor response to 
glucocorticoids (GCs) like prednisone and dexamethasone (i.e. GC resistance) are 
important adverse risk factors related to a higher risk of relapse and unfavorable 
overall survival. However, little is known about mechanisms of GC resistance in 
childhood ALL. Knowledge of these mechanisms may lead to renewed insights how 
to overcome GC resistance. Secondly, knowledge about the underlying causes of 
GC resistance may indicate which genes may be targeted using new therapies, 
thereby possibly increasing survival and decreasing the many side effects of GC 
treatment. The aim of the present study was to investigate possible causes of GC 
resistance in children with ALL.
   Chapter 2 reviews the current knowledge about mechanisms of GC resistance 
in childhood ALL. To induce apoptosis, GCs have to bind to the intracellular GC 
receptor (GR). One of the possible mechanisms for GC resistance is the presence 
of genetic mutations or polymorphisms in the GR gene that affect the function 
of the GR. Studies in a healthy population and in patients with a GC resistance 
syndrome have shown that specifi c polymorphisms in the GR gene (e.g. N363S, 
Bcl1) lead to increased sensitivity to GCs, whereas other polymorphisms and 
mutations in the GR gene (e.g. ER22/23EK) lead to decreased GC sensitivity.1-3 
No data are available on the relationship between genetic variants in the GR gene 
and resistance to GCs in childhood ALL. In Chapter 3 we addressed this issue in 
primary cells of patients at initial diagnosis of ALL. The coding region of the GR 
gene was screened for nucleotide variations in leukemic cells of 57 children with 
ALL. Besides six known polymorphisms, no mutations or new polymorphism in the 
GR gene were found. None of the polymorphisms in the coding region of the GR 
gene was linked to an unfavorable in vivo or in vitro response to prednisone. We 
therefore conclude that polymorphisms or mutations in the GR gene are no major 
contributors to GC resistance in childhood ALL.
   Another possible explanation for GC resistance in childhood ALL is an altered 
expression of the full length GR or the expression of specifi c 3’ splice variants 
of the GR. Two decades ago, the ligand binding capacity of the GR was found to 
be related to GC resistance,4, 5 although this could not always be confi rmed.6 In 
chapter 4 we examined the relationship between the base-line expression levels 
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of the GR and the three 3’ splice variants GR-alpha, GR-beta and GR-P and in vitro 
prednisolone resistance in leukemic cells taken at diagnosis from 54 children with 
ALL. A lower absolute expression level of the GR, but not the relative expression 
levels of the GR-alpha, GR-beta and GR-P splice variants, was associated with in 
vitro prednisolone resistance. Although the relationship between a low total GR 
expression and in vitro prednisolone resistance was statistically signifi cant, the 
interindividual differences in base-line expression of the GC receptor were rather 
small (~2-fold) compared to the > 1000-fold variation in level of resistance to 
prednisolone. Therefore, it seems likely that other mechanisms exist that may 
have a more pronounced contribution to GC resistance in pediatric ALL.
   It is known that the expression of the GR in leukemic cell lines can be induced 
by exposure to GCs, which may be necessary to induce apoptosis in ALL cells.7 
Therefore, in addition to the base-line expression level of the GR, GC resistance 
may be caused by the inability of cells to upregulate the expression of the GR 
upon GC exposure. Since the GR gene contains three different promoter regions 
of which one seems to be controlled by the GR itself, we studied the relationship 
between the expression of the different promoter-encoded GR variants and GC 
resistance in chapter 5. The expression levels of the 5 different 5’ GR promoter 
transcripts (1A1, 1A2, 1A3, 1B and 1C) both at base-line and after eight hours of 
prednisolone exposure appeared not to be related to in vitro prednisolone resistance 
in leukemic samples of children with ALL. Next, we tested the hypothesis that in 
vitro prednisolone resistant pediatric ALL cells were defective in upregulating GR 
levels upon in vitro GC exposure in contrast to leukemic cells from in vitro sensitive 
patients. Opposite to what is found in tissues in which GC exposure does not induce 
apoptosis, we showed a signifi cant upregulation of GR mRNA expression (and of 
the three 3’ splice variants GR-alpha, GR-beta and GR-P) after 8 hours of in vitro 
prednisolone exposure in pediatric ALL cells derived from children. However, the 
level of upregulation of total GR and the three 3’ GR splice variants did not differ 
between in vitro GC sensitive and resistant patients. Therefore we conclude that 
the degree of regulation of GR expression upon prednisone exposure does not 
contribute to GC resistance in childhood ALL. 
   The studies as mentioned above showed that resistance to GCs can not be explained 
by abnormalities in the GR itself. We next investigated the expression levels of the 
(co)chaperone molecules, which the GR needs to be in the correct confi guration to 
bind GCs and for the subsequent nuclear transportation. (chapter 6) The mRNA 
expression levels of the (co)chaperone molecules in leukemic cells taken at initial 
Chapter 8
110
diagnosis from 40 children with ALL were measured using quantitative real-time 
RT-PCR. No correlation was found between the expression levels of HSP-70, HSP-
40, HIP, BAG-1, HOP, HSP-90, P-23, FKBP-51, FKBP-52 and CYP-40 and in vitro 
prednisolone resistance. However, the underlying cause of GC resistance might 
be the inability of the GR and the different (co)chaperone molecules to form a 
complex, rather than the base-line mRNA expression levels of these molecules. 
It is diffi cult to study the formation of GR-(co)chaperone complexes since the 
binding and release of different components is a highly dynamic process. Besides 
base-line levels, also GC induced changes in the expression levels of co-chaperone 
molecules occur, which further complicates the study of functional GR complexes. 
It has previously been shown that the increase of FKBP-51 levels upon GC exposure 
was correlated to GC sensitivity in non-leukemic cells.8 However in chapter 7 we 
demonstrate that FKBP-51 is upregulated upon GC exposure in both GC sensitive 
and resistant ALL cells. 
   Since genetic aberrations and expression levels of the GR or its (co)chaperone 
molecules can not explain GC resistance in childhood ALL, we explored the signal 
transduction pathways that may be activated or repressed by GCs in ALL cells. 
Chapter 7 describes the results of a micro-array analysis of GC-responsive genes 
in childhood ALL. After exposing ALL cells of children in vitro to prednisolone for 3 
hours, no genes were differentially expressed compared to cells exposed to culture 
medium without prednisolone. However, after 8 hours of prednisolone exposure, 51 
genes were differentially expressed (p<0.05, FDR<10%) of which 39 genes were 
upregulated (median 2.4-fold) and 12 genes were downregulated (median 1.7-
fold). Twenty-one genes were not previously described as GC regulated genes. Two 
tumor suppressor genes, thioredoxin interacting protein (TXNIP) and zinc fi nger 
and BTB domain containing 16 (ZBTB16), were 3.7-fold and 8.8-fold upregulated 
respectively. Genes were functionally categorized in three major routes: i.e. MAPK 
pathways (9 genes), NF-κB signaling (11 genes) and carbohydrate metabolism (5 
genes). This study points to pathways that are used by GCs to trigger apoptosis in 
ALL cells. Future research is needed to functionally explore these pathways and to 
study whether abnormalities occur in these pathways that explain GC resistance 
in childhood ALL.
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DISCUSSION AND FUTURE PERSPECTIVES
N-terminal GR splice variants
Based on the studies described in the chapters 3 to 6, we concluded that 
abnormalities in the GR and associated proteins have only limited effect on 
the level of GC resistance in childhood ALL. However, more recently, new N-
terminal splice variants of GR-alpha have been described that are produced via 
translational regulatory processes.9 The level of expression of these splice variants 
differ signifi cantly among tissues and since each splice variant regulates both 
a common and a unique set of genes in the same cell, it was proposed that N-
terminal splice variants generate specifi city in GC-responsive gene transcription 
in different tissues. It is of interest to determine whether these splice variants 
contribute to GC induced apoptosis in ALL and whether an aberrant expression is 
linked to GC resistance. 
Posttranslational modifi cation
In the chapters 4 and 5, we observed that GR mRNA and protein levels were 
correlated in leukemic cell lines but at present it is unknown whether this is also true 
for primary patient samples. Posttranslational modifi cations might be important 
for the actual GR protein levels in the leukemic cell. In COS-1 cells expressing 
mouse GR, ubiquitination and proteasomal degradation of the GR was shown.10 A 
proteasome inhibitor effectively blocked GR protein down regulation. These cell 
line data suggest a role for the ubiquitin-proteasome pathway in regulating GR 
protein turnover. Another mechanism possibly regulating GR protein stability as 
well as its transcriptional activity is sumoylation. Sumoylation occurs through an 
interaction between GR and small ubiquitin-related modifi er-1 (SUMO-1). This 
may lead to specifi c degradation of the GR protein, but may also stimulate its 
transactivation capacity. It is hypothesized that sumoylation of the GR protein 
may regulate GR activity.11 It remains to be studied whether ubiquitination, 
proteasomal degradation and/or sumoylation are relevant for posttranscriptional 
regulation of the GR protein and whether GR protein levels are related to GC 
resistance in childhood ALL. 
TXNIP / ZBTB16
In the study as described in chapter 7, we found TXNIP and ZBTB16 to be 
upregulated upon GC exposure. These two tumor suppressor genes12 are interesting 
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candidates for the way GCs trigger the apoptotic pathway in childhood ALL. TXNIP 
may induce apoptosis by the repression of thioredoxin (TXN). TXN is a scavenger 
of ROS (reactive oxygen species), thereby preventing ROS induced cell death.13 
Secondly, TXN represses ASK1 (apoptosis signal-regulating kinase 1, MAP3K5), 
thereby preventing apoptosis.14 To address the contribution of these genes to GC-
induced apoptosis, one may study the effect of GC exposure of leukemic cell lines 
in which TXNIP and / or ZBTB16 have been silenced. 
MAPK pathways
In the study as described in chapter 7, we found nine GC-responsive genes 
that are involved in one or more of the mitogen activated protein kinase (MAPK) 
pathways. The proteins encoded by these genes are both positive and negative 
regulators of these MAPK pathways, but the net effect on proliferation is yet 
unclear. If the net effect is anti-proliferative, these genes may contribute to the 
induction of apoptosis in ALL. If the net effect is pro-proliferative, these genes 
contribute to cell survival and cell growth responses, which have been ascribed to 
these pathways as well.15, 16 Since the MAPK pathways are complicated networks, 
it is diffi cult to study these pathways in detail. The best way to study the genes 
regulated upon GC exposure, is to silence these single genes by RNAi and analyze 
the functional effect. Alternatively, selective blocking agents (e.g. RO-318220 as 
a blocker of DUSP-1 / MKP-117) may be used. If this decreases GC sensitivity, the 
blocked pathway might be relevant for GC induced apoptosis.
FLT3
Besides the top 51 of GC-responsive genes, also other genes are regulated upon 
GC exposure, but at a lower signifi cance level than used to select the genes 
as described in chapter 7. One of these genes is FLT3 (92nd most signifi cantly 
regulated gene, p=0.0004 and FDR=16%), which is upregulated in both sensitive 
and resistant leukemic cells. This gene is of special interest since the activity of 
FLT3 may be inhibited by tyrosine-kinase inhibitors such as PKC 412 and CEP-701. 
These tyrosine kinase inhibitors were shown to be effective in FLT3 mutated AML18 
and FLT3 overexpressing infant ALL.19 If GCs upregulate FLT3 expression, GCs 
might be used to “sensitize” leukemic cells to FLT3-inhibitors.
Carbohydrate metabolism
Analysis of gene expression profi les before and after GC exposure identifi ed fi ve 
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genes that were linked to carbohydrate metabolism (chapter 7). Upregulation 
of these genes may lead to an increased ATP production in the cell. In other 
tissues, GCs were also shown to upregulate metabolic genes involved in stress 
responses that require rapid and intense physical exertions.20 Therefore we 
conclude that these genes may not be involved in GC-mediated apoptosis. On 
the other hand, GC-resistance has been related to increased glycolysis.21 Our 
group recently showed that GC resistance correlates with a higher glycolytic rate 
in ALL cell lines.22 The glycolysis inhibitor 2-deoxy-D-glucose (2DG) selectively 
sensitized GC resistant, but not GC sensitive cell lines to GC induced apoptosis. 
If the degree of carbohydrate metabolism is indeed related to GC resistance in 
childhood ALL, strategies to circumvent this resistance may be developed. The 
increased carbohydrate metabolism might be antagonized with for example 2DG 
or TH-070.23 If our hypothesis might prove to be valid, these two compounds are 
especially interesting since they are already being tested in phase I/II studies for 
other malignancies. 
Selective GC agonists and antagonists
The last few years interesting compounds have become available which can be 
used in the search for the pathways of GC induced apoptosis and resistance 
mechanisms in childhood ALL. Some of these new compounds demonstrate 
equipotent anti-infl ammatory effects as compared to GCs, but with reduced side 
effects. One of these selective GC agonists, ZK216348, preferentially induces 
transrepression with little or no transactivating activity in a murine model of skin 
infl ammation.24 This compound may be used to study which pathway of gene 
transcription (transrepression or transactivation) is mainly used in childhood ALL 
cells. Secondly, if these compounds induce apoptosis in ALL cells in vitro, this 
might warrant further clinical evaluation in children with ALL. 
   Besides GC agonists, novel GR-alpha selective non-steroidal antagonists 
(NSGCAs) have been developed. Some agents have already been shown to 
antagonize the induction of glucose and glutamine metabolism, whereas other 
genes (e.g. pro-infl ammatory genes) were not affected.25 If these compounds 
do not disturb GC induced apoptosis in ALL cells, they are of interest for two 
reasons. In the fi rst place, these agents might decrease important side effects 
of GC treatment, like insulin resistance. Secondly, these agents might be used to 
sensitize resistant cells to GCs. Since we observed that GC-resistance is linked to 
an increased glycolytic rate in ALL cell lines22, it might be worthwhile to combine 
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GCs with NSGCA treatment in childhood ALL
(De-)acetylation of promoter regions
Acetylation of lysine residues of histones by histone acetyl transferase (HAT) 
coactivators is one of the proposed mechanisms that result in an “open-state” 
of the chromatine, thereby facilitating access of transcription factors to bind to 
target genes. On the other hand, histone deacetylases (HDACs) silence gene 
transcription by preventing access to promoter regions.26 Recently, SMAD6 was 
shown to silence GC-GR mediated transactivation together with HDAC3.27 The 
promoter region of GC responsive genes becomes deacetylated which results 
in decreased activity and thus decreased transactivation upon GC exposure. It 
has been hypothesized that Smad6 functions as a regulator of GC action.27 If 
SMAD6 suppresses GC induced apoptosis, this suggests an important role for the 
transactivating properties of GCs whereas in case of no effect the transrepression 
function via the inhibition of transcription factors like NF-κB and AP-1 might be 
more important for GC induced apoptosis in leukemic cells. Secondly, if increased 
SMAD6 expression will have a negative effect on GC induced apoptosis, it will be 
relevant to study the biological function of SMAD6 in ALL cells. 
   If the induction of apoptosis depends on transactivation of GC responsive genes, 
it is worthwhile to study the effect of HDAC inhibitors such as valproic acid.28 
Another HDAC inhibitor (depsipeptide / FK228) has been shown in our laboratory 
to have a cytotoxic effect in precursor B-ALL cells29, but its effect on the induction 
of apoptosis by GCs awaits further studies.
Side effects of GC treatment
There is a high interindividual variability in the occurrence of side effects upon 
prednisone / dexamethasone treatment in children with ALL.30 One of the possible 
reasons for this are polymorphisms in the GR as described in chapter 3. Using 
a dexamethasone suppression test, two polymorphisms (N363S and Bcl1) 
appeared to be related to increased sensitivity to GCs and one polymorphism 
(ER22/23EK) to decreased GC sensitivity in a healthy population.1-3 We showed 
that these polymorphisms were not related to GC sensitivity of ALL cells. (chapter 
3) However, these polymorphisms might affect the GC-responsiveness of normal 
tissues in the patient and may contribute to the occurrence of side-effects of GC 
treatment such as insulin resistance, increased body mass index, hypertension 
etcetera.3, 31 To investigate the relationship between GR polymorphisms and side 
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effects of treatment we started a prospective national study in children who are 
treated with the current DCOG treatment protocol ALL-10.
   One of the complications of GC treatment is the development of insulin resistance, 
sometimes leading to overt diabetes mellitus and the need of insulin therapy. 
Three insulin related genes are among the 51 signifi cantly GC regulated genes as 
described in chapter 7. INSR (insulin receptor), IRS2 (insulin receptor substance-
2), but also SOCS1 (suppressor of cytokine signaling 1) are upregulated. This last 
gene is reported to stimulate the ubiquitin-mediated degradation of IRS, leading 
to glucose intolerance.32 We speculate that the balance between SOCS1 and IRS2/
INSR expression determines the level of glucose intolerance. Future studies should 
address this, clinically very relevant, side effect.
   In conclusion, in this thesis we have shown that the main cause of GC resistance 
in childhood ALL is located downstream of GC binding to the GR. Although we have 
shown that the GR level is signifi cantly 2-fold lower in GR resistant compared to 
GC sensitive cells, this does not explain the more than 1000-fold interindividual 
difference in resistance to prednisolone among children with ALL. Other possible 
causes of GC resistance related to the GR (polymorphisms within the GR gene, 
(co)chaperone molecules and GR regulation upon GC exposure) have been 
excluded. A gene expression array study revealed several novel GC-responsive 
genes. Further research needs to explore the functional pathways of GC induced 
apoptosis and GC resistance in childhood ALL which is necessary to fi nd ways to 
circumvent GC resistance, that is a major adverse risk factor in childhood ALL. 
Secondly, the knowledge obtained by exploring GC mechanisms of action will lead 
to more specifi c, targeted GC therapy. This targeted therapy should have at least 
the same antileukemic effi cacy, but reduced side effects than the currently used 
drugs like prednisone and dexamethasone. 
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Samenvatting voor de leek
Acute lymfatische leukemie (ALL) wordt jaarlijks bij 100-120 kinderen vastgesteld 
en is daarmee de meest voorkomende vorm van kanker bij kinderen. De 
behandeling bestaat uit 2 jaar chemotherapie: medicijnen die als tablet of drank 
dan wel via een infuus worden gegeven. Desondanks lukt het bij een klein deel 
van de patiënten niet de leukemie weg te krijgen (complete remissie te bereiken) 
en komt bij een deel van de patiënten de ziekte terug (recidief), waarbij de kans 
op genezing aanzienlijk lager is dan bij de eerste diagnose. De laatste 35 jaar 
is, doordat steeds betere combinaties van medicijnen worden toegepast, de 
kans dat een kind een complete remissie bereikt en de ziekte niet terugkomt 
gestegen van bijna 0 tot 80%. Toch blijft ALL van alle vormen van kanker de 
belangrijkste doodsoorzaak bij kinderen. De kinderen bij wie de leukemie 
terugkomt zouden misschien baat hebben gehad bij een meer gerichte of zwaardere 
chemotherapeutische behandeling. Daarom is het van belang om bij of kort na 
de diagnose ALL een inschatting van de genezingskans te kunnen maken. Een 
van de risicofactoren voor het terugkomen van de ziekte is ongevoeligheid voor 
de medicijnen prednison en dexamethason. Dit zijn 2 medicijnen van hetzelfde 
soort, namelijk glucocorticoïden, welke zeer belangrijk zijn in de behandeling van 
ALL. Kinderen met ALL, die onvoldoende reageren op de eerste 7 dagen therapie 
waarin alleen prednison wordt gegeven, hebben een aanmerkelijk grotere kans op 
een recidief. Ook uit laboratorium onderzoek blijkt dat kinderen een aanmerkelijk 
grotere kans op een recidief hebben als hun leukemiecellen in de reageerbuis 
slecht doodgaan o.i.v. prednison. Ongevoeligheid, oftewel resistentie, voor 
prednison is dus een belangrijke voorspeller voor het terugkeren van de leukemie 
(en uiteindelijke overleving). Het is dan ook belangrijk de oorzaken van prednison 
resistentie te vinden zodat de resistente patiënten beter behandeld kunnen gaan 
worden. De kennis die hierover bestond bij aanvang van dit promotie onderzoek is 
samengevat in hoofdstuk 2. Aangezien er echter nog heel veel onduidelijk was, 
zijn de onderzoeken, zoals beschreven in dit proefschrift, verricht.
Het antileukemisch effect van prednison begint nadat prednison de leukemische 
cel binnendringt en aan de zogenaamde glucocorticoïd receptor bindt. Na binding 
worden er allerlei acties in de cel gestart, waaraan de leukemiecel uiteindelijk 
dood gaat. De erfelijke code voor de glucocorticoïd receptor ligt, zoals voor alle 
eiwitten, op het DNA en heet het glucocorticoïd receptor gen. Om het eiwit te 
maken wordt van het gen eerst een kopie gemaakt: het mRNA. Dit wordt daarna 
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gebruikt als mal om talloze kopieën van de glucocorticoïd receptor te maken. 
Afwijkingen in het glucocorticoïd receptor gen
Men kan zich voorstellen dat afwijkingen in het glucocorticoïd receptor gen zouden 
kunnen leiden tot een veranderde functie van deze receptor. Ons onderzoek of 
dergelijke afwijkingen gerelateerd zijn aan prednison resistentie is beschreven 
in hoofdstuk 3. Leukemische cellen van kinderen met ALL werden onderzocht 
op het voorkomen van afwijkingen (mutaties) in het glucocorticoïd receptor 
gen. Er werden geen afwijkingen gevonden. In 67% van de leukemie samples 
werden wel variaties in het DNA gevonden die polymorfi smen worden genoemd. 
Polymorfi smen zijn normaal voorkomende variaties in het DNA, die niet alleen in 
de leukemiecellen maar ook in de andere, gezonde lichaamscellen aanwezig zijn. 
Van 3 van de 6 gevonden polymorfi smen is echter wel bekend dat de glucocorticoïd 
receptor door deze veranderingen minder goed of juist beter werkt. Echter, uit 
onze studie bleek dat deze polymorfi smen niet de oorzaak zijn voor prednison 
resistentie bij kinderen met ALL. 
Het aantal glucocorticoïd receptoren en zijn varianten
Naast de hierboven genoemde variaties op DNA niveau is bekend dat bij het 
afl ezen van het DNA naar het mRNA een aantal varianten van de glucocorticoïd 
receptor kunnen ontstaan (GR-alpha, GR-beta en GR-P), mogelijk leidend tot een 
verminderde functie. In hoofdstuk 4 werd onderzocht of prednison resistentie 
verklaard kan worden door een veranderde expressie van deze receptor varianten. 
Het bleek dat prednison resistente leukemiecellen een verminderd aantal van 
de functionele glucocorticoïd receptor (GR-alpha) hebben. Het verschil tussen 
gevoelige en resistente patiënten was echter niet heel groot (ongeveer 2-voudig), 
zodat we betwijfelen of dit de belangrijkste oorzaak van prednison resistentie is. 
De verhouding tussen de functionele variant GR-alpha en de andere varianten 
(GR-beta en GR-P) was niet verschillend tussen gevoelige en resistente patiënten, 
zodat geconcludeerd werd dat deze niet-functionele receptor varianten niet 
bijdragen aan prednison resistentie. 
Blootstelling van leukemiecellen aan prednison leidt tot een toename van het aantal 
glucocorticoïd receptoren. (Hoofdstuk 5) Dit is bijzonder, aangezien in andere 
soorten lichaamscellen (die niet dood gaan o.i.v. prednison) het aantal receptoren 
juist afneemt. De mate van toename van het aantal receptoren in leukemiecellen 
bleek echter niet gerelateerd aan prednison gevoeligheid. De expressie van de 
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niet-functionele receptor varianten (GR-beta en GR-P) nam in gelijke mate toe, 
zodat de verhouding van functionele en niet-functionele receptoren hetzelfde bleef. 
Prednison resistentie kan daarom niet verklaard worden door een onevenredige 
toename van niet-functionele receptor varianten. Tevens is onderzocht of resistentie 
verklaard kan worden door het gebruik van specifi eke promoter sequenties in het 
DNA. Deze promoter sequenties zijn essentieel voor het opstarten van het maken 
van mRNA kopieën van het DNA. De glucocorticoïd receptor heeft minstens 5 
verschillende promoter sequenties. Ons onderzoek liet zien dat resistentie voor 
prednison niet afhangt van het type promoter dat gebruikt wordt voor de synthese 
van glucocorticoïd receptor mRNA bij kinderen met ALL. 
(Co)chaperonne eiwitten van de glucocorticoïd receptor
Om prednison goed te kunnen binden heeft de glucocorticoïd receptor een aantal 
eiwitten nodig, die de receptor in zo’n vorm houden dat binding goed mogelijk 
is. Deze eiwitten heten chaperonne en cochaperonne eiwitten. In hoofdstuk 6 
wordt het mogelijk belang van dergelijke (co)chaperonne eiwitten voor prednison 
resistentie onderzocht. De mRNA expressie van deze (co)chaperonne moleculen 
(HSP-70, HSP-40, HIP, BAG-1, HOP, HSP-90, P-23, FKBP-51, FKBP-52 and CYP-
40) is zeer heterogeen en kan geen verklaring zijn voor prednison resistentie bij 
kinderen met ALL.
Paden langs welke prednison leukemiecellen doodt
Nadat prednison aan de glucocorticoïd receptor bindt wordt een proces in gang 
gezet waaraan de leukemiecel uiteindelijk dood gaat. Dit proces bestaat uit een 
of meer complexe cascade(s) van signalen waarover nog relatief weinig bekend 
is. Aangezien de studies in de hoofdstukken 3 tot 5 lieten zien dat afwijkingen 
in de glucocorticoïd receptor en zijn (co)chaperonne moleculen niet de oorzaak 
zijn van prednison resistentie, zou resistentie mogelijk verklaard kunnen worden 
door afwijkingen in deze signaal-cascades. Om dit verder te onderzoeken werd 
een micro-array studie gedaan. Dit is een moderne techniek, waarbij van 14500 
genen tegelijk het expressie niveau gemeten kan worden. Zoals beschreven in 
hoofdstuk 7, resulteerde blootstelling van leukemiecellen aan prednison in een 
veranderde expressie van 51 genen; de expressie van 39 genen nam toe terwijl 
de expressie van 12 genen juist verlaagd werd. Twee van de genen die verhoogd 
tot expressie kwamen o.i.v. prednison blootstelling coderen voor eiwitten die het 
ontstaan van tumoren kunnen onderdrukken (tumor-suppressor genen). Van de 
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51 genen gereguleerd door prednison zijn een aantal gerelateerd aan paden die 
te maken hebben met cel-overleving en -deling (MAP kinase paden en genen 
gerelateerd aan NF-κB) dan wel de energie voorziening van de cel. Een van de 
hypothesen omtrent prednison resistentie die verder onderzoek behoeft is dat 
resistente ALL cellen wellicht beter in staat zijn de energie productie na blootstelling 
aan prednison te verhogen, wat ze helpt te ontkomen aan celdood. 
Een beter inzicht in de paden die uiteindelijk prednison geïnduceerde celdood 
veroorzaken lijkt nodig om de oorzaken van prednison resistentie te vinden. Als 
deze paden bekend zijn, kan mogelijk meer gerichte therapie (“targeted therapy”) 
ontwikkeld worden, waarbij resistentie omzeild kan worden en prednison de 
leukemiecellen kan doden met zo min mogelijk bijwerkingen voor de gezonde 
cellen.
OVERWEGINGEN VOOR DE TOEKOMST
Nieuwe glucocortoid receptor varianten
Op basis van de studies zoals beschreven in dit proefschrift (hoofdstuk 3 - 6) 
concluderen we dat veranderingen van de glucocorticoïd receptor en daaraan 
gerelateerde moleculen slechts een beperkt effect hebben op de mate van prednison 
resistentie bij kinderen met ALL. De laatste tijd zijn er echter nog weer nieuwe 
varianten beschreven van de glucocorticoïd receptor. Het zou interessant zijn ook 
van deze receptor varianten de invloed op prednison resistentie te onderzoeken. 
Veranderingen op eiwit niveau
In de hoofdstukken 4 en 5 zagen we dat de hoeveelheid mRNA en eiwit van 
de glucocorticoïd receptor aan elkaar gecorreleerd zijn in leukemische cel lijnen. 
Hoewel het waarschijnlijk is dat dit ook in de leukemiecellen in de patiënt het 
geval is, dient dit nog wel onderzocht te worden. Het zou kunnen zijn dat ondanks 
gelijke hoeveelheden mRNA, het receptor-eiwit in resistente cellen sneller wordt 
afgebroken dan in gevoelige cellen. 
Paden langs welke prednison leukemiecellen doodt
In de studie als beschreven in hoofdstuk 7 vonden we 2 paden (MAPK paden en 
paden gerelateerd aan NF-κB) waarvan verschillende genen gereguleerd worden 
onder invloed van prednison blootstelling. De relatie van deze paden met prednison 
geïnduceerde celdood moet verder onderzocht worden. Een van de manieren om 
deze paden te onderzoeken is door de paden op bepaalde plekken te blokkeren 
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(door genen uit te schakelen). Als een dergelijke blokkade de gevoeligheid voor 
prednison vermindert, dan is dat betreffende pad mogelijk belangrijk voor het 
celdodend effect van prednison. 
Een andere conclusie die werd getrokken na de studie als beschreven in hoofdstuk 
7, is dat in de paden die zorgen voor de energie voorziening van de cel een 
aantal genen worden gereguleerd o.i.v. prednison blootstelling. Mogelijk zijn 
cellen die resistent zijn voor prednison beter in staat hun energie productie te 
verhogen, zodat ze kunnen overleven. Ander onderzoek heeft dit inmiddels nog 
meer aannemelijk gemaakt. Het zou daarom interessant zijn de mogelijkheden te 
onderzoeken om de energievoorziening van de leukemiecel te remmen, zodat de 
cel gevoeliger wordt voor het celdodend effect van prednison. 
Bijwerkingen van prednison behandeling
Er is veel verschil tussen de ALL patiënten met betrekking tot het optreden 
van bijwerkingen van de prednison. De bijwerkingen die kunnen optreden zijn 
o.a.: hoge bloeddruk, bol, opgezet gezicht (cushingoïd uiterlijk of maangezicht), 
overgewicht, suikerziekte en gedragsstoornissen. Hoewel deze bijwerkingen 
overgaan na het stoppen van de therapie, kunnen ze wel heel lastig zijn voor 
de patiënt. Een van de mogelijke oorzaken voor het verschil in gevoeligheid 
voor deze bijwerkingen tussen patiënten zijn de verschillende polymorfi smen 
zoals beschreven in hoofdstuk 3. Hoewel we hebben laten zien dat deze niet 
de oorzaak zijn van prednison resistentie, zouden ze wel de oorzaak kunnen zijn 
van het wel of niet optreden van bijwerkingen in de patient. Deze mogelijkheid 
wordt onderzocht in het nieuwe ALL-10 behandel protocol van de SKION (Stichting 
KinderOncologie Nederland). 
Samenvattend hebben we in dit proefschrift laten zien dat de belangrijkste oorzaak 
van prednison resistentie bij kinderen met leukemie moet liggen nadat prednison 
is gebonden aan de glucocorticoïd receptor. Hoewel resistente leukemiecellen 
over minder glucocorticoïd receptoren beschikken dan gevoelige, lijkt dit toch niet 
de belangrijkste oorzaak van het meer dan 1000-voudige verschil in resistentie 
tussen prednison gevoelige en resistente leukemiecellen. Andere variaties van 
de glucocorticoid receptor als oorzaak van prednison resistentie (mutaties en 
polymorfi smen, (co)chaperonne moleculen en regulatie van de receptor door 
prednison) werden uitgesloten. In een gen expressie studie vonden we nieuwe 
genen die gereguleerd worden door prednison blootstelling. Verdere studies naar 
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de functionele paden die leiden tot prednison geïnduceerde celdood en oorzaken 
van prednison resistentie bij kinderen met ALL is nodig. Inzicht in de wijze waarop 
prednison leukemiecellen doodt zou kunnen leiden tot meer specifi eke en gerichte 
therapie, die hetzelfde antileukemisch effect heeft als prednison, maar met minder 
bijwerkingen gepaard gaat. 
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van dit proefschrift, ook de opleiding tot onderzoeker afgerond. Ik hoop dat ik in 
de toekomst beide opleidingen nog veel zal gebruiken, in mijn klinisch werk als 
kinderoncoloog en in het werk als onderzoeker op het zeer uitgebreide gebied in 
de kinderoncologie van wat we nog niet weten.
Bij het afsluiten van een periode hoort het bedanken van mensen. Ik hoop echter 
dat ik al tijdens de afgelopen jaren blijk heb gegeven van mijn waardering voor 
de mensen met wie ik samenwerkte, anders komt die waardering wel erg laat. 
Desalniettemin toch maar: 
In de eerste plaats grote waardering voor mijn promotor: Rob Pieters. Begin 1999 
kwam je als nieuw sub-hoofd van de afdeling kinderoncologie naar Rotterdam, 
en ik heb het afgelopen jaar aan den lijve ondervonden dat een nieuwe werkplek 
“wel even wennen is”. Daarbij had je toen meteen een onervaren fellow, die 
onderzoek wilde doen. Zo kwam ik als eerste promovendus op een lab, waar 
behalve een post-doc (Monique den Boer) en een analist (Karin Kazemier) nog 
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Dan mijn copromotoren: Jules Meijerink en Monique den Boer. Dank voor jullie 
begeleiding! Jules, niet copromotor vanaf het allereerste begin, want je kwam pas 
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Monique en je hebt je daar vervolgens vol overgave in gestort. Ik heb veel van 
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klinische dokter moleculaire biologie bij te brengen, compleet met de bijbehorende 
technieken. Ik zal die kennis hopelijk nog lang gebruiken.
Monique, copromotor van het eerste uur, toen je begon in een lab waar nog niets 
was. Dank voor je kritische blik op mijn artikelen. Ik denk dat vooral jij me hebt 
geleerd een wetenschappelijk artikel te schrijven en je hebt me ingewijd in de 
diepere krochten van de statistiek, zeker ten tijde van onze array experimenten. 
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Karel Hählen. Beste Karel, in 1998 nam jij me samen met Rob aan als fellow 
kinderoncologie. Dank voor het in mij gestelde vertrouwen. In mijn jaren als 
fellow (en daarna) heb ik veel van je geleerd over de kinderoncologie. Regelmatig, 
als ik weer met een vraag kwam, wist je te vertellen dat dat in het verre verleden 
was onderzocht, waarbij je vaak ook nog het betreffende artikel in de kast had. Jij 
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kamer (eerst ver weg gestopt in de kelder als fellow, later mochten we op de gang 
voor “echte” stafl eden). Ik mis je nog regelmatig als ik in Groningen alleen op 
mijn kamer zit. Dank voor je luisterend oor en je goede adviezen met betrekking 
tot het onderzoek. 
Dank aan de “nieuwe” collega’s in Groningen. Voor mij was het verfrissend om 
na jaren Sophie in een andere omgeving te gaan werken. Ik hoop dat het voor 
jullie net zo verfrissend is. Vanaf het eerste moment voelde ik me zeer welkom en 
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directe en snelle “Tissing-“ dan wel “Rotterdamse” manier van communiceren.
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